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Niemann-Pick C1 is essential for Ebola virus infection and a target of small 
molecule inhibitors  
 
Abstract 
 
 Ebolavirus (EboV) is a highly pathogenic enveloped virus that causes 
outbreaks of zoonotic infection in Africa.  The clinical symptoms are manifestations of 
the massive production of pro-inflammatory cytokines in response to infection and in 
many outbreaks, case fatality rate exceeds 75%.  The unpredictable onset, ease of 
transmission, rapid progression of disease, high mortality and lack of effective 
vaccine or therapy have created a high level of public concern about EboV.  Here we 
report the properties of a benzylpiperazine adamantane diamide-derived compound 
identified in a screen for inhibitors of EboV infection.  We found that the inhibitor is 
specific, reversible, and that the target(s) for inhibition are present in cells and not in 
virus particles. The compound is not an inhibitor of acid pH-dependent endosome 
protease activity, which is required for EboV infection.  Treatment of cells with this 
compound causes accumulation of cholesterol in late endosomes and lysosomes 
(LE/LY), suggesting it inhibits one or more proteins involved in regulation of 
cholesterol uptake into cells.  Using mutant cell lines and informative derivatives of 
the inhibitor, we found the inhibitor target is the endosomal membrane protein 
Niemann-Pick C1 (NPC1).  NPC1 is a polytopic LE/LY membrane protein that 
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mediates uptake of lipoprotein-derived cholesterol into cells.  We find that NPC1 is 
essential for EboV infection, that NPC1 binds to the protease-cleaved GP1 subunit of 
the EboV glycoprotein, and that the anti-viral compound inhibits infection by targeting 
NPC1 and interfering with binding to GP1. Furthermore, analysis of viral variants 
resistant to the anti-viral compound revealed that the residues which confer 
resistance are located on the surface of the receptor binding domain of GP1. 
Combined with the results of previous studies of GP structure and function, our 
findings support a model of EboV infection in which cleavage of the GP1 subunit by 
endosomal cathepsin proteases removes heavily glycosylated domains to expose the 
N-terminal domain, which is a ligand for NPC1 and regulates membrane fusion by the 
GP2 subunit.  Thus, NPC1 is essential for EboV entry and a target for anti-viral 
therapy. 
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Chapter 1  
 
Introduction 
 
Breaking into cells: Viral entry proteins, host encoded triggering factors, 
and the mysteries of Ebola virus entry. 
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Virus entry 
As obligate intracellular parasites viruses must deliver their genetic material 
into the host cell in order to propagate and spread. The first major physical 
barrier that a virus must bypass in order to productively infect a cell is the plasma 
membrane. Viruses have evolved highly specialized mechanisms for getting past 
the protective lipid bilayer that surrounds the host cell. All viruses must enter the 
cell through a mechanism that leaves the host undamaged so that it may 
continue to subvert the resources of the host for its own replication and spread. 
For non-enveloped viruses, which are protected by a proteinaceous shell, entry is 
facilitated by penetration and disruption of the host membrane by viral coat 
proteins. Enveloped viruses protect their genetic material by acquiring a lipid 
bilayer during budding from the parent cell and must facilitate fusion of the virus 
and host membranes in order to deliver their genome. A high kinetic barrier must 
be overcome to bring the two membranes in close enough proximity for fusion to 
occur.   
 
Structural Rearrangements Facilitate Membrane Fusion 
Enveloped viruses have evolved a diverse set of specialized surface 
expressed viral glycoproteins (GPs) that serve to lower the kinetic barrier to 
membrane fusion (Chernomordik and Kozlov, 2003). These fusion proteins lower 
this kinetic requirement by providing free energy when they undergo an 
energetically favorable structural rearrangement as they bring the virus and host 
membrane in close proximity. Despite a wide range of differences in both fusion 
! $!
!"#$%&'()*+',$-%'.$
./,'$')%00()$
1(2%34,%/&$54,%/&$6/)($
3/)2*7/&$
891(:%;$
<4&=:($
>/&3/)2*7/&*:$$
+.*&0($+/46:(=$'/$$
2(2?)*&($34,%/&$
@&,()7/&$/3$!"A$
34,%/&$6(67=($
>(::$
B%)4,$
1/,'$$
5*+'/)$
!"#$
!"A$
>(::$
B%)4,$
a b c 
d e f 
Figure 1-1. A generalized mechanism for enveloped virus entry. (a-c) As the virus approaches 
the host cell the attachment domain (GP1), interacts with a triggering factor provided by the target 
cell. This then causes a structural change that releases GP1 imposed constraints on the fusion 
subunit (GP2). GP2 extends towards the cellular membrane to facilitate fusion peptide (yellow) 
insertion into the cellular lipid bilayer, thus, forming what is termed the extended pre-hairpin 
intermediate. (d) GP2 continues to undergo structural rearrangements as it continues to fold to its 
lowest energy level conformation, a trimer of hairpin. As GP2 begins to fold back on itself the virus 
and host membranes begin to deform as they are bought in close proximity to each other. (e) 
These membrane deformations lower the energetic barrier between the two lipid bilayers and a 
hemifusion intermediate begins to form where the outer lipid bilayers begin to mix while the inner 
bilayers remain separate. (f) As GP2 undergoes its final rearrangements which bring the fusion 
peptide and transmembrane regions of GP2 in close proximity in a trimer of hairpins, a fusion pore 
beings to form and finally expands allowing for delivery of viral contents into the cell.  
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protein structure and cellular signals that trigger their conformational changes, all 
classes of virus fusion proteins share a generalized fusion mechanism. Viral 
fusion proteins have two membrane interacting domains that facilitate the 
juxtaposition of the membranes: a hydrophobic patch that ultimately inserts into 
the host membrane termed the fusion peptide (F) and a trans-membrane (TM) 
domain at the C-terminus that anchors the protein in the viral membrane. Upon 
stimulation from the host cell, the GP undergoes a structural rearrangement 
leading to a homo-trimeric extended pre-hairpin intermediate that connects the 
two membranes (Figure 1-1a-c). During the formation of this intermediate, the 
hydrophobic fusion peptide is released from its pre-fusion confirmation and 
extends to imbed in the target (cellular) membrane (Figure 1-1c). The reaction 
proceeds as the fusion protein folds back onto itself to form a ‘trimer-of-hairpins’, 
which function to bring the fusion peptide (cellular membrane) and the 
transmembrane domain (viral membrane) together (Figure 1-1d). The two 
membranes deform as they are brought into close proximity, lowering the 
energetic barrier between the two bilayers until a hemifusion intermediate forms. 
During hemifusion, the outer leaflets merge while the inner leaflets of the lipid 
bilayers remain separate (Figure 1-1e). As the conformational rearrangement is 
completed, the hemifusion intermediate develops into a fusion pore, which 
expands to allow delivery of the contents of the virion into the host cell (Figure 1-
1f). The structural rearrangements that occur between the prefusion and 
postfusion confirmations of the viral GP provide the free energy required to 
catalyze membrane fusion.  This generalized model of membrane fusion has 
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been established over the course of over thirty-years from the accumulation of 
several pioneering structural and functional studies of virus membrane fusion.  
  
Structural classifications of virus fusion proteins: Class I, II, and III 
Viral membrane glycoproteins can be categorized into three classes of 
proteins based on structural homology between their extracellular domains in 
their prefusion and postfusion conformations (reviewed in White et al., 2008 and 
Harrison, 2008). Class I proteins form trimeric oligomers in both the pre- and 
postfusion conformations that are mostly α-helical in secondary structure. A 
broad range of viral families have class I fusion proteins including 
Orthomyxoviridae (with the classical example of influenza HA), Retroviridae, 
Paramyxoviridae, Coronaviridae, Filoviridae, and Arenaviridae. In contrast, class 
II fusion proteins are composed primarily of ß-strands and are expressed as flat 
dimers on mature virions. Triggering of class II fusion proteins converts the 
dimers into trimerized projections from the viral membrane, which subsequently 
fold back to form a trimer-of-hairpins composed of !-sheets. Flaviviridae, 
Togaviridae, and Bunyaviridae all encode class II fusion proteins. Class III viral 
proteins share structural characteristics with both class I and class II viral 
proteins and are composed of a mix of !-stands and "-helicies. The fusion 
proteins from Rhabdoviridae and Herpesviridae are class III fusion proteins. 
Although the pre- and postfusion confirmations have been solved for all classes 
of fusion proteins, we know the most about the structure, function, and triggering 
of class I fusion proteins. 
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Class I fusion proteins 
 Class I viral proteins are the most widely studied class of viral fusion 
proteins and much of our insight into viral fusion proteins, and specifically class I 
proteins, comes from groundbreaking structural work done by Wiley and Skehel 
that solved the prefusion conformation of influenza HA (Wilson et al., 1981), the 
postfusion conformation of HA2 (Bullough et al., 1994) and the conformation of 
the uncleaved precursor HA0 (Chen et al., 1998). Class I glycoproteins are often 
synthesized as a polypeptide precursor (GP0) that must be cleaved post-
translationally into two domains. This processing step requires the action of a 
host cell protease late in the biosynthetic process or an extracellular enzyme 
after budding. This cleavage, which is N-terminal to the fusion peptide, creates 
two functional domains in the GP: a transmembrane domain that mediates fusion 
(GP2) and an ectodomain (GP1) that serves as a clamp that maintains GP2 in its 
pre-fusion confirmation. For most class I fusion proteins the cleavage of the poly-
protein is required for infectivity; indeed, viral particles containing only uncleaved 
influenza HA0 or HIV gp160 are noninfectious (Kawaoka and Webster, 1987; 
McCune et al., 1988; Bosch and Pawlita, 1990). This trimer of hetero-dimers 
created by the cleavage takes on a metastable conformation, a state in which 
GP1 forms an energetic barrier by providing stabilizing contacts that prevent 
rearrangement of GP2 into the post-fusion conformation. GP2 contains structural 
domains that are crucial for membrane fusion, including a N-terminal fusion 
peptide (F), an "-helical heptad repeat region 1 (HR1), a linker region, a second  
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Figure 1-2. Class I viral fusion proteins have a trimeric coiled-coil post-fusion conformation. 
(a) During fusion the extended pre-hairpin intermediate folds back to form a hairpin in which the C-
terminal transmembrane domain of the fusion protein (depicted here in brown, attached to the viral 
membrane) comes into close proximity to the N-terminal fusion peptide (depicted in yellow, 
attached to the host membrane). This conformational change facilitates fusion of the two 
membranes. HR1 (blue) forms the central coiled coil of the hairpin, while HR2 (green) packs into 
the groves of the HR1 coiled coil to form a trimer of hairpins or a 6-HB. (b) Atomic resolution 
structures of the post-fusion conformations of several representative class I viral fusion proteins. 
Only the transmembrane subunit (or GP2) is depicted. The N-terminal fusion loops and the C-
terminal transmembrane regions are not resolved. Structures are color coded as in (a). PDB files 
are as follows: Ebola GP2 (1EBO), HTLV-1 gp21 (1MG1), HIV-1 gp41 (1ENV), SARS S2 (2BEQ), 
and Flu HA2 (1HTM). 
a 
b 
Ebola GP2 HTLV-1 gp21 HIV-1 gp41 SARS S2 Flu HA2 
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"-helical heptad repeat region (HR2), and a C-terminal transmembrane (TM) 
region which anchors the domain to the viral envelope. During membrane fusion, 
GP2 irreversibly converts into a stable postfusion conformation, in which the N-
terminal fusion peptide is adjacent to the C-terminal TM. For all class I proteins, 
this postfusion trimer-of-hairpins conformation is termed the six helix-bundle 
(6HB) because it is composed of a trimer of HR2 that “zips up” into the grooves 
of the central "-helical HR1 core (Figure 1-2a). The 6HB form of the fusion 
protein is the most stable conformation that the GP takes on during the fusion 
process. Although a broad range of viruses with extremely diverse sequences 
have class I GPs, the central 6HB of the postfusion conformation remains 
structurally conserved (Bullough et al., 1994; Kobe et al., 1999; Weissenhorn et 
al., 1997; Weissenhorn et al., 1998; Supekar et al., 2004)  (Figure 1-2b). The 
transition to 6HB formation is an irreversible rearrangement because the 
postfusion conformation represents the lowest energy state of the protein. Thus, 
it is essential that viruses trigger conversion to the postfusion conformation only 
when they are in close enough proximity to a target membrane to initiate 
productive fusion. The GP1 of class I fusion proteins have evolved several 
regulated mechanisms to sense cellular ‘triggers’ and initiate fusion only when 
the virus is close enough to the target membrane. 
 
Entry mechanisms  
 Dissection of the membrane distal subunit of GP have revealed that this 
protein has two functions: the first is to provide stabilizing contacts with the 
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prefusion form of GP2, or the so called “clamp” function, and the second is to 
sense a host provided signal that releases the restraints on GP2, known as the 
“triggering” function. GP1 must also mediate attachment to the plasma 
membrane of target cells, which can be mediated by specific or non-specific 
attachment factors and, occasionally, by a specific receptor-virus interaction. 
Here, we will make a distinction between virus receptors and attachment factors, 
a distinction that is not often made in the literature; we will refer to host factors on 
the cell surface that simply bind to the GP as attachment factors. Attachment 
factors can form specific interactions such as the binding between sialic acid 
(SA) and influenza HA (Weis et al., 1988), or can be broader factors that bind 
non-specifically to the sugars on the surface of the GP, as is the case for the 
interactions between DC-SIGN and HIV, SARS-CoV, Influenza or EboV 
(Geijtenbeek et al., 2000; Alvarez et al., 2002; Wang et al., 2008; Yang et al., 
2004; Marzi et al., 2004). Attachment factors serve to tether the virus to the 
plasma membrane, facilitating a subsequent interaction with an entry receptor on 
the cell surface, or mediating virus uptake into the cell through the endocytic 
pathway, upon which the virus may then encounter its necessary trigger. In 
contrast, a virus entry receptor binds to the GP and induces a conformational 
change that ultimately leads to the fusion of the virus and host membranes. Host 
factors that trigger this fusion reaction can act in a one-step manner, where a 
single signal leads to the conformational change needed to trigger fusion, or in a 
multi-step manner, where two or more host factors are required to induce 
sequential and step-wise conformational rearrangements necessary for 
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membrane fusion. 
 
Host factors that trigger: a one-step or multi-step mechanism 
 Various examples of host factor triggers are known for both one- and multi-
step mechanisms of fusion protein activation. To date only two types of host 
signals trigger single-step fusion mechanisms: either low pH or receptor binding. 
In the case of influenza HA, the virion is internalized following attachment to sialic 
acid on the cell surface, and is trafficked through the endocytic pathway until the 
pH of the endosome drops to a level capable of triggering a pH dependent 
structural rearrangement responsible for releasing the fusion peptide (Skehel et 
al., 1982). The interaction of the ecotropic murine leukemia virus (E-MLV) 
glycoprotein (SU) with its receptor murine cationic amino acid transporter 1 
(MCAT-1) provides an example of a receptor-induced one-step fusion 
mechanism (Albritton et al., 1993). The binding of the receptor binding domain 
(RBD) on the E-MLV SU with MCAT-1 triggers structural changes that reveal a 
disulfide bond isomerization CXXC motif in the clamping domain of SU (Davey et 
al., 1997; Wallin et al., 2006). Exposure of this motif leads to a disulfide bond 
rearrangement that releases the covalent bond between SU and the fusion 
subunit (TM), allowing for the subsequent transformation to the 6HB postfusion 
state (Wallin et al., 2004; Wallin et al, 2005; Li et al., 2007).  
 By contrast, multi-step fusion mechanisms utilize either a combination of 
receptors at the cell surface or a combination of receptor binding followed by an 
endosomal triggering step. One of the best-characterized two-step triggering 
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mechanism is that of HIV-1. During entry the HIV-1 distal unit of GP (gp120) 
interacts with its two receptors in a sequential manner. Initially, CD4 binding to 
gp120 induces a conformational change that moves aside an immunoprotective 
domain and reveals the co-receptor binding site (Dalgleish et al., 1984; 
Klatzmann et al., 1984). The revealed binding site is capable of interacting with a 
co-receptor, either CXCR4 or CCR5, which leads to the release of gp41 (GP2 
equivalent) and catalysis of membrane fusion (Choe et al., 1996; Deng et al., 
1996; Dragic et al., 1996; Feng et al., 1996). Still, not all two-step receptor 
interactions simply move aside domains to reveal the final triggering interaction. 
The interaction between the avian leukosis virus type A (ALV-A) envelope and its 
receptor, Tva, induces a conformational change into a stable extended pre-
hairpin fusion intermediate, in which the fusion peptide is embedded in the target 
membrane. This intermediate only converts into the postfusion 6HB conformation 
after subsequent exposure to low pH (Mothes et al., 2000). In yet another 
permutation of a two-step triggering mechanism, the binding of the S glycoprotein 
of SARS coronavirus with its cell surface receptor, angiotensin-converting 
enzyme 2 (ACE2), potentiates the cleavage of the S glycoprotein with the pH 
dependent endosomal protease cathepsin L, which ultimately triggers membrane 
fusion (Simmons et al., 2005). Although numerous virus receptors have been 
identified, the exact manners in which they are able to propagate a binding signal 
into large structural rearrangements are not fully understood. The regions that 
constitute the RBD in HIV GP120 and MLV gp70 are distinct from the regions 
that stabilize GP2 and can, in the case of MLV, remain functional in absence of 
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covalent linkage to the remainder of Env (Barnett et al., 2001). The findings that 
domains for attachment, triggering, and stabilization of the transmembrane 
subunit are distinct is consistent with the suggestion of Wiley and colleagues that 
viruses acquired multistep regulation of Env function by incorporating functional 
domains into a basic fusion machine composed of the clamp and transmembrane 
domains (Rosenthal et al., 1998). Regardless of how many steps an entry 
mechanism may have, the identification of the key host triggers of virus entry are 
essential for understanding the ways in which viruses have evolved to use these 
host factors for productive infection.  
 
Identifying essential host factors 
 For the cases described above, the host factors and receptors have been 
identified with a combination of experimental approaches using genetics, 
biochemistry, and chemical biology. One commonly used genetic method for 
receptor identification involves the transfer of host genes responsible for virus 
entry into non-permissive cell lines; a method that was used to identify the 
receptor for E-MLV, as well as the CXCR4 co-receptor for HIV (Albritton et al., 
1989; Feng et al., 1996). This method requires the identification of non-
permissive cell lines as well as the construction of cDNA libraries from 
permissive cells. Another commonly used method involves physically capturing a 
proteinaceous host factor through biochemical purification of host proteins 
capable of binding the receptor binding subunits of the viral fusion proteins. The 
virus receptors for SARS-CoV (ACE2), the paramyxovirus Nipah virus 
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(ephrinB2), and the New World arenavirus Machupo (transferrin receptor 1) were 
identified using artificially engineered ligands composed of the receptor binding 
subunit of GP fused to the Fc domain of human IgG (Li et al., 2003; Radoshitzky 
et al., 2007; Negrete et al., 2005).  After binding to the surface of permissive 
cells, these engineered proteins were used to co-immunoprecipitate their 
corresponding receptor proteins, which were then identified through mass-
spectrometric analysis. This method is potentially hindered by the cellular 
location of the receptor, the affinity with which the GP binds to the cellular 
receptor, and the capability of mass-spectrometric analysis to identify the protein. 
Indeed, if the host factor is not a proteinaceous binding partner, then neither of 
these two methods would reveal its identity. In the cases of low pH induced 
fusion of influenza HA and cathepsin protease-dependent fusion mechanism of 
SARS-CoV, chemical inhibitors of known function were used to tease out the 
relevant host factors (Yoshimura et al., 1982; Simmons et al., 2005; Huang et al., 
2006). However, these discoveries required significant in vitro characterization to 
confirm that the inhibitors were indeed acting in the manner suspected because 
of the high probability of off-target effects for small molecules. More often than 
not, follow-up experiments that confirm the roles of the identified host factors 
employ a combination of all of these experimental tools. Although the viral 
receptors and host factors that mediate entry for several major human pathogens 
with class I fusion proteins have been identified, relatively little is known about 
the entry mechanism of the highly pathogenic Ebola virus. Recent studies have 
suggested that Ebola virus has a unique entry mechanism that involves drastic  
! "%!
EboV TaFV BdbV RestV SudV MarV 
64.3 65.5 57.9 56.3 27.1 EboV 
73.5 57.4 55.1 27.4 TaFV 
57.8 54.7 27.3 BdbV 
60.6 26.4 RestV 
28.0 SudV 
MarV 
Identity (percent) matrix based on full length GP 
sequences 
Zaire, 1995 
Mayinga 
EboV 
SudV 
RestV 
TaFV 
BdbV 
MarV 
Bundibugyo, 2007 
Cote d’Ivoire, 1994 
Pennsylvania 
Gulu 
Boniface 
Yambio, 2004 
Angola, 2005 
Musoke 
DCR, 1999 
Figure 1-3. Phylogenetic analysis reveals six species of filoviruses. (a) A phylogenetic tree 
comparing the full length viral genomes of representative strains of ebolavirus and marburgvirus. 
The two genera can be divided into one marburg species, Marburg marburgvirus (MarV), and five 
ebola species, Zaire ebolavirus (EboV), Sudan ebolavirus (SudV), Taï Forest ebolavirus (TaFV), 
Reston ebolavirus (RestV) and Bundibugyo ebolavirus (BdbV). (b) A percent identity matrix was 
produced using amino acid sequences of the full length glycoproteins of the reference strains for all 
filovirus species.  
a b 
! "&!
cleavage of the ectodomain and subsequent unidentified triggering steps.    
 
Ebola virus as a class I envelope virus 
 Infection by the Filoviridae family of viruses, which consists of the two 
genera Marburgvirus and Ebolavirus, often causes a highly lethal hemorrhagic 
fever syndrome in humans and nonhuman primates. The two genera can be 
divided into a single marburg species, Marburg marburgvirus (MarV), and five 
ebola species, Zaire ebolavirus (EboV), Sudan ebolavirus (SudV), Taï Forest 
ebolavirus (TaFV, formerly Cote d’Ivoire ebolavirus), Reston ebolavirus (RestV) 
and Bundibugyo ebolavirus (BdbV) (Figure 1-3a). While the genomes of the 
ebolavirus species differ from each other by only about 30-40% at the nucleotide 
level, the differences between the two genera are much greater, at approximately 
70%  (Towner et al., 2008).  
These filamentous viruses have non-segmented negative stranded RNA 
genomes which are enveloped by a host-derived membrane acquired through 
virus budding. During Ebola virus infection, fusion of the virus and host 
membranes is mediated by the viral membrane glycoprotein (GP), a class I viral 
fusion protein, which forms trimers of hetero-dimers on the surface of virions 
(Figure 1-4a). The two subunits that make up the mature dimer are GP1 and 
GP2; GP1 mediates viral adhesion and regulates GP2, the transmembrane 
subunit that drives viral fusion (Watanabe et al., 2000; Manicassamy et al., 
2005). As with other class I proteins, EboV GP is synthesized as a polyprotein 
that is cleaved during biosynthesis in the Golgi by a furin-like protease into GP1 
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Figure 1-4. Schematic of filovirus virions and glycoprotein. (a) Filovirus virions are long 
filamentous particles with a negative stranded RNA genome bound to proteins, which together 
make the ribonucleoprotein complex core. The core is surrounded by the matrix protein VP40 
which lies between the core and the envelope. The glycoprotein (GP), the only virus protein that 
lies on the surface of the virion, forms trimerized spikes. (b) GP is a type I viral glycoprotein. The 
precursor polyprotein is cleaved in the Golgi by furin between amino acids 501 and 502, splitting 
the protein into GP1 and GP2 domains. GP1, the distal subunit that mediates virus attachment, is 
divided into two central domains, a N-terminal protease resistant core (17k) and a heavily 
glycosylated domain composed of the glycan cap (Glyc Cap) and a highly variable mucin-like 
domain (Mucin). GP2, the membrane proximal domain that mediates fusion, is composed of an 
internal fusion loop (F), followed by two canonical type I heptad repeat regions (HR1 and HR2), 
and a transmembrane domain (TM) that anchors the protein into the virus membrane. (c) After 
furin cleavage, GP1 and GP2 remain covalently linked through a disulphide bond (s-s) and 
trimerize to form spikes on the virion surface. 
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 and GP2 (Volchkov et al., 1998) (Figure 1-4b). However, unlike the previously 
mentioned examples of class I GPs (such as HIV, E-MLV, and influenza), the 
furin cleavage site between EboV GP1 and GP2 is dispensable for both entry 
and pathogenesis (Wool-Lewis and Bates, 1999; Neumann et al., 2007).  After 
furin cleavage, GP1 and GP2 remain disulfide linked and trimerize to form a 
functional GP (Figure 1-4c) (Ito et al., 1999; Ito et al., 2001; Takada et al., 1997; 
Watanabe et al., 2000; Wool-Lewis and Bates, 1998). GP, the sole viral protein 
on the virion surface, drives a multistep entry process that requires attachment, 
uptake into vesicles via a macropinocytic like mechanism (Saeed et al., 2010; 
Nanbo et al., 2010), trafficking to the late endosome/ lysosome (LE/LY), and 
fusion with the limiting membrane of the LE/LY.  
 
EboV attachment factors 
Although little is know about the minimal requirements for EboV fusion, the 
search for host factors that mediate fusion has lead to the identification of several 
factors that enhance EboV infection. These factors include molecules that bind 
non-specifically to the sugars present on the heavily glycolyated GP, such as 
DC-SIGN (dendritic cell-specific ICAM3-grabbing non-integrin) and L-SIGN (liver 
and lymphnode SIGN), which likely enhance infection by concentrating virions on 
the cell surface (Alvarez et al., 2002; Marzi et al., 2004). By contrast, other 
enhancement factors that do not bind directly to the GP, such as !1 integrins and 
the TYRO3 family tyrosine kinase receptor Axl, act to enhance infection through 
indirect mechanisms like promotion of downstream protease activity or induction 
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of macropinocytosis respectively (Shimojima et al., 2006; Shimojima et al., 2007; 
Schornberg et al., 2009; Hunt et al., 2011).   Finally, a recently identified 
enhancement protein, T cell immunoglobulin and mucin domain-containing 1 
(TIM1), appears to bind EboV GP. However, several cells that do not express 
this protein are still highly susceptible to EboV infection, thus indicating that it is 
not an essential entry factor (Kondratowicz et al., 2011). Although each of these 
factors enhance EboV entry by enhancing virion attachment or uptake, they are 
not essential for infection; cells that lack these proteins are still susceptible to 
EboV entry. The early search for essential host factors for EboV entry was 
impeded by two key characteristics of the virus. First, filoviruses are able to infect 
a vast range of cell types from many different species (Wool-Lewis and Bates, 
1998), so the resulting lack of non-permissive cell lines limits the usefulness of 
gain of function genetic approaches. Secondly, binding of a soluble GP1 ligand to 
the surface of permissive cells did not reveal a high-affinity binding site on the 
plasma membrane that could be purified by affinity chromatography and 
identified by mass spectroscopy. To date, chemical approaches have yielded the 
few clues we have as to which essential host factors may function in EboV entry. 
 
Low pH and Cathepsins are essential EboV Host Factors 
Early studies of Ebola virus entry revealed that entry occurred in a low pH- 
dependent manner. Lysosomotropic agents such as bafilomycin-A, ammonium 
chloride (NH4Cl), and chloroquine, which each prevent the acidification of the 
endosome, inhibited EboV-GP mediated entry  (Wool-Lewis and Bates, 1998; 
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Takada et al., 1997). However, unlike other low pH dependent viruses such as 
influenza, in vitro exposure of virions to low pH did not inactivate the virus, 
indicating that low pH alone was not sufficient to trigger entry.   
Subsequently, our lab and others have demonstrated that EboV entry 
requires the acid dependent endosomal proteases cathepsins, a family of related 
enzymes that function optimally at pH 5.0 in the late endosomes and lysosomes 
of cells (Chandran et al., 2005; Schornberg et al., 2006). These studies showed 
that cathepsin B (CatB) is an essential host factor, while CatL serves an 
accessory role. In vitro cleavage with purified cathepsins suggests that 
proteolysis of the GP by cathepsins is likely a multi-step process involving 
several cysteine proteases. Digestion of virus with CatB or CatL cleaves the 
130kD GP1 molecule down to an 18kD intermediate, which then undergoes 
further processing by CatB into a stable 17kD intermediate (Chandran et al., 
2005 and Schornberg et al., 2006). The protease cleaved virus remains fully 
infectious and sensitive to the cysteine protease inhibitor E-64 and to the 
endosomal acidication blocking drug bafilomycin A (Figure 1-5) (Schornberg et 
al., 2006). Follow-up experiments on the role of cathepsins in entry have mapped 
the cathepsin cleavage site to amino acid 190 in GP1 and have suggested that in 
vitro protease cleavage increases EboV GP binding and infectivity (Kaletsky et 
al., 2007; Dube et al., 2009; Hood et al., 2010). Cleavage of GP is necessary but 
not sufficient for entry, thus, suggesting that additional host factors activate the 
GP fusion mechanism (Figure 1-5). Although it is possible that another  
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Figure 1-5. Role of cathepsins B and L in EboV entry. EboV is taken up and trafficked to the late 
endosomes (LE) of cells. Once in the LE, cathepsins (Cat) B and/or L act on the GP1 domain and 
cleave off a significant portion of the GP1 protein, leaving an intermediate fragment that is only 
18kD in size. This intermediate then undergoes further cathepsin B processing to form a 17kD 
post-cathepsin intermediate. This intermediate is still fully infectious and is able to overcome 
specific CatB/L blocks to infections, but remains sensitive to the cysteine protease inhibitor E-64 or 
the inhibitor of endosomal acidification bafilomycin A (Baf-A), suggesting that there is still a role for 
another as of yet unidentified LE host factor (HF) in EboV entry. 
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endosomal protease or other LE/LY factor may mediate the final triggering step 
for Ebola virus fusion, there is mounting evidence that receptor binding may play 
a critical role in filovirus entry.  
 
Evidence for a filovirus receptor 
There are three lines of evidence that suggest that Ebola virus entry may 
require an active receptor: (1) mutagenesis and infection studies show that single 
point mutants in a 150 amino acid region of the highly conserved N-terminal 
domain of GP1 decrease infectivity (Brindley et al., 2007; Manicassamy et al., 
2005; Manicassamy et al., 2007; Mpanju et al., 2006), (2) a putative minimal 
receptor binding domain (RBD) has been identified in GP1 that binds to 
permissive cells (Kuhn et al., 2006 and Dube et al., 2009) and (3) the atomic 
resolution structure of the prefusion Ebola GP suggests that highly variable and 
heavily glycosylated domains of the protein may have evolved to shield this 
putative minimal RBD from immune recognition (Lee et al., 2008).  
  Studies utilizing recombinant proteins that fuse the putative receptor-
binding domain (RBD) of GP1 to the Fc domain of human IgG, have given us our 
first clues into the potential role for a receptor in Ebola virus entry. Kuhn et al. 
identified a homologous 151-amino acid fragment in MarV GP1 and EboV GP1 
(AA 54-201) that bound specifically to permissive cell lines but showed no 
binding to non-permissive lymphocyte cell lines (2006). In contrast, full-length 
GP1-Fc did not bind to permissive cells.  Both the MarV and EboV GP-Fc  
! ##!
Figure 1-6. Structure of the prefusion EboV GP prior to cathepsin cleavage and a modeled 
post-cleavage GP. (a) A space fill model of the atomic resolution prefusion trimer structure of 
EboV GP (PDB 3CSY, left, view from top; right, view from side). Glycans that were resolved in the 
structure are depicted here in gray. The region of the protein that corresponds to the glycan cap is 
shown as orange spheres. The “minimal” RBD is depicted here in pink with key residues important 
for binding highlighted in light green. The remainder of GP1, shown in red, constitutes the base or 
clamping domain. The fusion loop of GP2, depicted here in yellow, nestles into an adjacent GP1 
monomer. The HR1 region of GP2, shown in blue, forms the stalk and cradles the base of the 
chalice bowl created by GP1. b) Predicted model of the GP trimer after cathepsin mediated 
removal of the glycan cap. The site of cathepsin cleavage has been mapped to amino acid 190 in 
GP1, which is consistent with complete removal of the glycan cap and subsequent exposure of the 
RBD.  
Top Side 
a 
Top Side 
b 
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constructs inhibited the entry of retroviruses pseudotyped with either filovirus 
envelope, suggesting an overlap in receptor usage between these highly 
divergent filovirus species (Kuhn et al., 2006). Subsequent experiments 
narrowed down the minimal RBD to residues 90-149 of GP1, found that the 
fusion protein bound in a saturable manner at very high concentrations, and 
indicated that certain cells have an extensive intracellular pool of RBD-Fc binding 
partners (Dube et al., 2009; Dube et al., 2010). The mapping of the minimal RBD 
as well as the localization of the cathepsin cleavage site correlates well with 
structural data from the atomic resolution structure of the prefusion EboV GP.  
 
Structure of EboV GP suggests protease cleavage reveals the RBD 
 The prefusion GP structure shows that the trimer takes on a chalice like 
conformation (Figure 1-6a); the three GP1 subunits come together to form the 
bowl of the chalice with the putative receptor binding sites present on the inside 
of the bowl, while the GP2 helices cradle the bowl and form the stalk of the 
chalice (Lee et al., 2008). The inside of the chalice bowl and the RBD are at least 
partially occluded by both a glycan cap  (Figure 1-6a), a domain of the protein 
that includes several N-linked glycans, and a mucin-like domain, a highly variable 
domain with several N- and O-linked glycosylation sites that are not present in 
the crystal structure, but has been modeled to lay on top of the bowl (Lee et al., 
2008). Interestingly, the cathepsin cleavage site lies within a disordered loop that 
bridges the portions of GP1 containing the RBD to the glycan cap, suggesting 
that cathepsin proteases serve to remove these heavily glycosylated  
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Figure 1-7. Model of ebola virus entry circa 2010. EboV particles bind to attachment factors on 
the cell surface and are internalized by macropinocytosis. Cleavage of EboV GP by the endosomal 
cysteine proteases cathepsins exposes the receptor binding domain. Additional unidentified host 
factors are required to trigger virus fusion with the host cell membrane. There could be one or more 
host factors that trigger fusion. Data suggests that binding to an unidentified intracellular receptor 
may play a key role in entry. 
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immunoprotective domains to expose a functional receptor binding site (Figure 1-
6b) (Lee et al., 2008). The findings of a structurally distinct RBD that is revealed 
only in the LE/LY compartments after cathepsin cleavage, and the presence of 
an extensive intracellular pool of RBD binding partners (Dube et al., 2010), 
provide compelling evidence for the role of an intracellular receptor during EboV 
entry (Figure 1-7). 
 
Using small molecules to identify a missing intracellular host factor 
 A central step towards understanding the mechanism of Ebola virus entry 
is the identification of the putative intracellular receptor. However, as previously 
mentioned, the nearly ubiquitous nature of permissive cells combined with the 
fact that the RBD binding site may be in an intracellular compartment, has 
prevented the productive use of biochemical or gain-of-function genetic tests to 
identify a GP1 binding partner. Instead, our lab decided to take an unbiased 
chemical biology approach to take advantage of a key characteristic of small 
molecule inhibitors: that the size and hydrophobicity of many small molecules 
allows them to diffuse past the cellular membrane, making them more likely to be 
capable of targeting a potential intracellular host factor. We employed a vesicular 
stomatitis virus-pseudotyping (VSV) system to develop an entry assay that could 
be utilized in BSL2 for a high-throughput screen (HTS) to identify small molecule 
inhibitors of EboV entry. A single cycle VSV system engineered to express firefly-
Luciferase in the place of the VSV glycoprotein (VSV-G) was used for the assay. 
The viruses were pseudotyped with either VSV-G or EboV-GP. VSV-G was 
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chosen as a counter screen since it also enters through a low pH dependent 
mechanism. The entry assay scored a molecule as positive for EboV entry 
inhibition if the molecule inhibited EboV-GP but not VSV-G, thus eliminating hits 
that were overly toxic to the cells, affected the post-entry steps of VSV infection, 
or inhibited viral entry through a mechanism shared by both glycoproteins. In 
collaboration with the Institute of Chemistry and Cell Biology (ICCB) at Harvard 
Medical School, our lab screened a chemical library of approximately 50,000 
compounds, as well as a pool of known bioactive compounds.  Six unique hits 
specific to EboV-GP were identified, referred to as compounds 3.0, 4.0, 5.0, 6.0, 
7.0, and 8.0. These compounds exhibited IC50s of less than 5µM, and no 
apparent cell cytotoxicity. The bioactive screen yielded a number of cysteine 
protease inhibitors (including E-64d), as well as specific cathepsin B and L 
inhibitors, validating the ability of this screen to identify EboV-specific inhibitors. 
In addition to the inhibitors of the known EboV host factors, the bioactive screen 
and subsequent confirmatory experiments identified a number of surprising 
compounds that inhibited EboV entry. These compounds include sertraline, 
tamoxifen, alverine, and U18666A. 
 
Scope of the Dissertation 
 A central step towards understanding the mechanism of Ebola virus entry 
is the identification of the missing host factors that activate fusion, a task that has 
long eluded those studying EboV entry. In an attempt to use an unbiased 
chemical biology approach to identify chemical probes that target the suspected 
! #(!
but unidentified host factors involved in EboV entry, our lab performed a HTS. 
The screen identified several small molecules and bioactives that inhibited EboV 
entry. The data presented in this dissertation represents the body of work that 
followed the screen, work that ultimately lead us to the identification of Niemann-
Pick C1 as a novel host factor for EboV entry and a target of one of the 
compounds.  
 The initial characterization of the inhibitors established that they were 
specific and reversible, that the target was likely in the cell rather than the virus 
particles, and that they did not disrupt cathepsin activity. We demonstrated that 
the compounds were active against protease cleaved virus, suggesting that they 
possibly inhibited a novel entry step downstream of cathepsin cleavage. In an 
attempt to further characterize the compounds, we studied the physiochemical 
properties of the compounds identified in the small molecule and bioactive 
screen. We noticed that many of the compounds identified in the screen were 
hydrophobic amines and had physiochemical properties that suggested they act 
like cationic amphiphilic drugs (CAD). We tested our compounds for the ability to 
induce cholesterol accumulation in the LE/LY of cells, a common phenotype 
observed in cells treated with CADs. Compound 3.0 and its potent derivative 3.47 
lead to accumulation of cholesterol in the LE/LY of cells. Because 3.0 and 3.47 
did not share the physiochemical properties characteristic of CADs, we 
investigated the possibility that these inhibitors could be targeting components of 
the cholesterol uptake pathway. Systematic analysis of components of the LE/LY 
cholesterol uptake pathway, through the use of human fibroblasts from patients 
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with cholesterol transport disorders and siRNA knockdown of genes, revealed 
that NPC1 played a critical role in EboV entry. Experiments in knockout cells 
established that NPC1 expression was strictly required for EboV entry but that 
cholesterol transport activity was not required. Consistent with a role as a 
possible receptor, we found that only cathepsin cleaved GP bound to NPC1.  
Studies conducted with 3.0 and its derivatives confirmed that these compounds 
directly target NPC1, that they are able to prevent the binding of cleaved GP to 
NPC1, and that the NPC1-GP interaction is important for virus entry. Finally, the 
observation that mutations in the RBD of GP1 conferred resistance or sensitivity 
to the inhibitor strengthens the claim that the interaction between NPC1 and 
cleaved GP may represent the long-sought-after virus-receptor interaction. 
 The identification of the NPC1 as the missing intracellular receptor for 
EboV fills in a substantial gap in the knowledge of the mechanisms that mediate 
EboV entry. Fortunately, the findings in this dissertation fit nicely into the 
established model for Ebola virus entry. They reveal an elegant mechanism by 
which the virus is able to shed its immuno-protective domain using host 
cathepsin proteases in the LE/LY. Thus, the receptor-binding site is revealed only 
once it is in the LE/LY of cells where the receptor, NPC1, is located. The 
implications of these findings are explored in detail in the discussion. 
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Chapter 2 
 
Identification of NPC1 as an essential host factor for EboV entry 
 
The data presented in this chapter is derived in part from the following published work. 
 
Côté M.*, Misasi J.*, Ren T.*, Bruchez A.*, Lee K., Filone C.M., Hensley L., Li Q., Ory D., 
Chandran K., Cunningham J. Small molecule inhibitors reveal Niemann–Pick C1 is 
essential for Ebola virus infection. Nature. 447, 344-348 (2011). 
*Contributed equally. 
Contributions: KC and TR performed the inhibitor screen. KL synthesized and purified 
inhibitor analogs. AB and TR tested inhibitors in infection assays. AB tested cellular 
phenotypes of inhibitors. AB performed initial characterization of the inhibitors. TR, AB, 
JM, and MC carried out infection assays with pseudotyped viruses. AB did infection 
assays in primary human fibroblasts.   AB performed microscopy.  TR and MC 
performed siRNA experiments. JM purified recombinant glycoprotein.  MC and JM 
designed and performed binding assays. MC performed immunoprecipitation. Ebola 
virus infections were performed in the lab of LH by CF.  
Figure contributions: MC produced the data for Figures 2-10b, 2-11b, 2-13, and 2-
14b. TR produced the data for Figure 2-10c. CF produced the data for Figure 2-11c. JM 
produced the data for Table 2-3 and Figure 2-12. AB and JM collaborated to produce 
the data for Figure 2-14a. AB produced all other Figures.
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Abstract: 
Ebola virus (EboV) is a highly pathogenic enveloped virus that causes 
outbreaks of zoonotic infection in Africa. Here we report the identification of several 
novel and bioactive compounds that inhibit EboV entry. In characterizing the antiviral 
activities of these compounds, we found that they are reversible and that the target(s) 
for inhibition are present in cells and not in virus particles. The compounds are not 
inhibitors of the known EboV host factors cathepsin proteases or low pH. Treatment of 
cells with one of the compounds, a novel benzylpiperazine adamantane diamide-
derived compound, leads to cholesterol accumulation in the late endosome and 
lysosome (LE/LY) of cells, suggesting that the compounds target one or more proteins 
involved in regulation of cholesterol uptake in cells. Using mutant cell lines and siRNA 
knockdown of key proteins in this pathway, we show that the endosomal membrane 
protein Niemann-Pick C1 (NPC1) is essential for EboV infection.  We find that NPC1 
expression but not cholesterol transport activity is essential for infection and that it binds 
to the virus glycoprotein (GP).  Combined with the results of previous studies of GP 
structure and function, our findings support a model of EboV infection in which cleavage 
of the GP1 subunit by endosomal cathepsin proteases removes heavily glycosylated 
domains to expose the N-terminal domain, which is a ligand for NPC1 and regulates 
membrane fusion by the GP2 subunit.  Thus, NPC1 is an essential host factor for EboV 
entry. 
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Introduction: 
Ebola virus (EboV) infection often causes a highly lethal hemorrhagic fever syndrome in 
humans and nonhuman primates.  The clinical symptoms are manifestations of the 
massive production of pro-inflammatory cytokines in response to infection, and mortality 
has exceeded 75% in many of the outbreaks (Zampieri et al, 2007).  The unpredictable 
onset, ease of transmission, rapid progression of disease, high mortality and lack of 
effective vaccine or therapy have created a high level of public concern about EboV 
(Geisbert and Jahrling, 2004). EboV entry is a multistep process that requires an 
interaction with multiple host factors, thus making it an attractive target for potential 
therapeutic interventions. 
During Ebola virus infection, fusion of the virus and host membranes is mediated 
by the viral membrane glycoprotein (GP), a class I viral fusion protein, which forms 
trimers of hetero-dimers on the surface of virions. The two subunits that make up the 
mature dimer are GP1 and GP2; GP1 mediates viral adhesion and regulates GP2, the 
transmembrane subunit that drives viral fusion (Watanabe et al., 2000; Manicassamy et 
al., 2005). GP drives a multistep entry process that requires attachment, uptake into 
vesicles, trafficking to the late endosome/ lysosome (LE/LY), and activation of GP fusion 
activity. Ebola GP mediated entry is dependent on both low pH and the acid dependent 
endosomal proteases cathepsins. Previous studies have shown that fusion activity is 
dependent on cleavage of the GP1 subunit by cathepsins (Chandran et al., 2005; 
Schornberg et al., 2006). Cleavage exposes the N-terminal domain of GP1, which may 
be a receptor ligand (Kuhn et al., 2006; Lee et al., 2008; Dube et al., 2009; Hood et al., 
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2010). Cleavage of GP is necessary but not sufficient for entry, suggesting that 
additional host factors activate the GP fusion mechanism.  
A central step towards understanding the mechanism of Ebola virus entry is the 
identification of the missing host factors that activate fusion. The lack of known non-
permissive cell lines for EboV infection has prevented the use of the same gene-transfer 
based, gain-of-function approaches that have been successful in identifying receptors 
for other enveloped viruses (Albritton et al., 1989; Feng et al., 1996). Furthermore, the 
likely intracellular nature of the host-factor interaction has confounded the use of 
biochemical co-purification and identification techniques. Thus, our lab has instead 
taken an unbiased chemical biology approach to identify chemical probes that may 
target the suspected, but yet unknown host factors involved in EboV entry. 
 
Results: 
A. Initial characterization of compounds identified by screening 
To identify chemical probes that target EboV entry host factors, we screened a 
library of small molecules and identified six novel molecules (3.0, 4.0, 5.0, 6.0, 7.0, 8.0) 
that inhibit infection by vesicular stomatitis virus particles (VSV) pseudotyped with EboV 
GP, but not VSV particles pseudotyped with native G or Lassa Fever virus (LFV) GP 
(Table 2-1). The IC50s of these compounds were each less than 5µM and there were 
no apparent cell cytotoxicities observed.  
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Table 2-1. EboV GP entry inhibitors identified through HTS 
† IC50 and IC90 values were estimated from dose response curves obtained using  in the 
following manner. Vero cells were grown in media containing increasing concentrations of 
compounds for 90 min before the addition of VSV particles encoding luciferase and 
pseudotyped with EboV GP (VSV-Luc-GP). Virus infection was graphed as a percent of 
luminescence units (RLU) relative to cells exposed to DMSO vehicle alone and IC values 
were estimated from these graphs. Data is representative of three independent experiments. 
N=6.  *Potent derivatives of parent compounds 3.0 and 5.0 that were discovered through 
structure activity relationship (SAR) studies. 
† † 
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Subsequent studies of structure and (antiviral) activity relationships (SAR) with 
compounds 3.0 and 5.0 resulted in identification of derivatives 3.47 and 5.10, which 
exhibited greater anti-EboV activity than their parent compounds.  Thus, our screen 
identified a panel of small molecules specifically capable of inhibiting EboV GP 
mediated viral entry. 
 
B. Pre-incubation of virus with the compounds is not sufficient to block entry 
 Virion pre-incubation experiments were performed to determine whether 
compounds 3.0-8.0 block EboV entry by acting on the viral particle itself.  Virus particles 
were incubated with inhibitors (!10 µM) at 37°C for two hours (Figure 2-1a). 
Subsequent addition of the virus-inhibitor mixtures to the medium of susceptible cells 
reduced the concentration of inhibitor by 100-fold to !10 nM, well below the 
concentrations previously observed to be active during infection. Drug pre-incubation 
with virus did not inhibit infection under these conditions (Figure 2-1b). In contrast, when 
cells were exposed to !10 µM of the inhibitors during infection, the levels of VSV EboV 
GP-dependent infection were reduced by "80%. These findings suggested that the 
target(s) of each of the inhibitors were in the cell, rather than associated with the virus 
particles. It is important to note that these findings do not exclude reversible inhibition of 
an inhibitor target on virus particles.  
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Figure 2-1. Pre-incubation of virus with inhibitors does not block entry. (a) Schematic of order 
of addition assays. Vero cells were seeded onto 12-well cell culture plates.  Compounds 3.47 (1µM), 
4.0 (10µM), 5.10 (2µM), 6.0 (1µM), 7.0 (2µM),  8.0 (10µM) and a vehicle control (DMSO) were added 
to cells or virus in the following three manners. (1) Cells were pre-incubated with inhibitors (white 
bars)  at 37°C for two hours prior to infection and virus was added to the cells in the presence of the 
inhibitor. (2) Virus and inhibitors were added to cells simultaneously (gray bars) and inhibitors 
remained on the cells during infection. (3) Virus was pre-incubated with the inhibitors (black bars) in 
a small volume at 37°C for two hours before the addition of  the mixture to the cells. The mixture was 
diluted 100x when added to the cells. (b) Cells were incubated with VSV particles encoding GFP and 
pseudotyped with EboV GP. Virus infection is reported as percent GFP-positive cells relative to cells 
exposed to DMSO vehicle alone. Data are mean ± s.d. (n=3) 
a 
b 
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C. Order of addition experiments 
 The temporal relationships between inhibitor action and infection were 
investigated. We performed a series of washout experiments in order to investigate the 
reversibility of the inhibitors. Vero cells were incubated for one hour at 37°C with an 
inhibitory concentration of the antiviral compounds or positive control ammonium 
chloride (NH4Cl), which buffers and thus prevents acidification of lysosomes. 
Subsequently, the cells were cooled down to 25°C, and virus was added to allow the 
particles to bind in the presence of inhibitors. After 30 minutes, cells were washed to 
remove unbound virus and fresh media containing inhibitors were added back to the 
wells. Infection was initiated by raising the temperature to 37°C. At the indicated times 
post infection, media containing the inhibitors were removed and replaced with fresh 
media without inhibitor.  No inhibition of infection was observed when the antiviral 
compounds were removed from culture media immediately before infection was initiated 
(Figure 2-2a). In contrast, incubation with the inhibitors for two hours after exposure to 
virus particles was sufficient to achieve the same degree of antiviral activity obtained by 
prolonged inhibitor treatment. These findings indicate that inhibitor action is reversible 
and occurs within the first two hours of infection. 
 Time-of-addition experiments were also performed to further characterize the 
minimal window upon which EboV entry is susceptible to the antiviral activity of 
inhibitors. Virus was again bound to cells at 25°C for 30 minutes, and infection was 
allowed to synchronously progress upon shift to 37°C. Either 20µM of EboV inhibitors, 
or 30mM NH4Cl were added at various time points post infection.  
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Figure 2-2. Kinetic experiments indicate that inhibitors can act up to 30 minutes post-
infection. (a)!"#$%!&#''(!)#$#!*+&,-./#0!1%$!%+#!2%,$!./!3456!)*/2!&%78%,+0(!39:;!<9:!;!=9:;!>9:;!49:;!?9:!@A:!
µM),! /2#! 'B(%(%7./$%8*&! .C#+/! .77%+*,7! &2'%$*0#! @DE<6';! 3:7FG;! %$! H#2*&'#! &%+/$%'! @IFJKG9! 6#''(!)#$#!
/2#+!&%%'#0!/%!A=56!.+0!VSV EboV-GP virus!).(!.00#0!/%!.''%)!/2#!8.$L&'#(!/%!-*+0! *+!/2#!8$#(#+&#!%1!
&%78%,+0(9!M#''(!)#$#!).(2#0!/%!$#7%H#!,+-%,+0!H*$,(!.+0!7#0*.!&%+/.*+*+C!/2#!*+2*-*/%$!).(!.00#0!-.&N!
/%!/2#!)#''(9!O+1#&L%+!).(!*+*L./#0!-B!$.*(*+C!/2#!/#78#$./,$#!/%!34569!P/!/2#!*+0*&./#0!L7#(!8%(/!*+1#&L%+;!
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&#''(! ./! A=56;! )#''(! )#$#! ).(2#0! /%! $#7%H#! ,+-%,+0! H*$,(;! .+0! *+1#&L%+! ).(! *+*L./#0! -B! $.*(*+C! /2#!
/#78#$./,$#! /%! 34569! F#0*.! ).(! $#8'.&#0! )*/2! *+2*-*/%$! &%+/.*+*+C! 7#0*.! ./! /2#! *+0*&./#0! L7#(! 8%(/Q
*+1#&L%+9!6%+&#+/$.L%+(!%1!&%78%,+0(!.$#!/2#!(.7#!.(!*+!@.G9!Virus infection is reported as percent GFP-
positive cells relative to cells exposed to DMSO vehicle alone. Data are mean ± s.d. (n=3) 
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Similar to NH4Cl, each of the compounds were effective up through 30 minutes, but 
much less at 60 minutes following infection (Figure 2-2b). Taken together, these studies 
indicate that the newly identified compounds are reversible inhibitors of infection, and 
suggest that the antiviral target(s) exists within cells to mediate EboV trafficking and/or 
fusion. 
 
D. Compounds do not target known EboV host factors: Low pH or Cathepsins 
 Previous studies indicate that the acid pH-dependent endosomal cysteine 
proteases cathepsin B and L are necessary but not sufficient for Ebola virus infection. 
We thus sought to determine whether the newly identified anti-EboV compounds 
inhibited cathepsin protease activity. In an initial experiment, we examined whether the 
antiviral compounds change the pH of the LE/LY where cathepsin B and L reside. This 
was achieved using LysoTracker Red, a probe that consists of a fluorophore attached to 
a weak base, which diffuses freely through membranes until it becomes protonated and 
concentrated in low pH compartments (Lemieux et al., 2004). We found that 
concentrations of the antiviral compounds corresponding to the IC99 had no effect on 
accumulation of LysoTracker within cells, while the buffering agents NH4Cl and 
chloroquine ablated LysoTracker staining (Figure 2-3a). Corroborating this result, we 
found that the anti-EboV compounds have no effect on the entry of VSV particles 
pseudotyped with the acid pH-dependent glycoproteins of LCMV or VSV (Figure 2-3b). 
These findings strongly suggest that the antiviral activities of the newly  
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LysoTracker + DMSO 
LysoTracker + 4.0 
LysoTracker + 7.0 LysoTracker + 8.0 
LysoTracker + 3.0 
LysoTracker + 6.0 
LysoTracker + 5.0 
LysoTracker + Chloroquine LysoTracker + NH4Cl 
Figure 2-3. Inhibitors do not prevent acid dependent accumulation of LysoTracker nor entry of 
acid dependent viruses VSV and LCMV. (a) Cells were pre-incubated at 37°C for one hour with 
media containing the following compounds at their IC99, 3.0 (20µM), 4.0 (10µM), 5.0 (10µM), 6.0 
(5µM), 7.0 (5µM), 8.0 (20µM), chloroquine (20µM), NH4Cl (10mM) or vehicle control (DMSO). The 
cells were exposed to LysoTracker (red) at 37°C and then imaged ten minutes post-incubation. The 
presence of low pH compartments is indicated by the concentration of LysoTracker in those 
compartments (red) and the cell nuclei were counterstained with Hoechst stain (blue). (b) Vero cells 
were grown in media containing 3.0 (20µM), 4.0 (10µM), 5.0 (10µM), 6.0 (10µM), 7.0 (10µM), or 8.0 
(20µM) for 90 min before the addition of VSV particles encoding luciferase and pseudotyped with 
either EboV GP, VSV G or LCMV GP. Virus infection is reported as percent of relative luminescence 
units (RLU) normalized to cells exposed to DMSO vehicle alone. Data are mean ± s.d. (n=3) and is 
representative of three experiments. 
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Figure 2-4. Compounds inhibit infection by protease-cleaved virus particles. (a) EboV 
pseudotyped particles were incubated with thermolysin (THL) and cleavage of GP1 was analyzed by 
immunoblot following deglycosylation with PNGaseF. (b) Vero cells were treated with 3.47 (1µM), 4.0 
(10µM), 5.10 (2µM), 6.0 (1µM), 7.0 (2µM),  8.0 (10µM) or DMSO and exposed to native or 
thermolysin-cleaved VSV EboV GP particles. (c) Native or thermolysin-cleaved VSV EboV GP 
particles were pre-incubated with the inhibitors in a small volume at 37°C for two hours before the 
addition of  the mixture to the cells. The mixture was diluted 100x when added to the cells. Virus 
infection is reported as percent GFP-positive cells relative to cells exposed to DMSO vehicle alone. 
Data are mean ± s.d. (n=3) 
a b 
c 
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identified inhibitors are not simply dependent on buffering the endosomal and lysosomal 
pH.  
Previous studies revealed that the endosomal protease cathepsin B is essential 
for EboV infection because it cleaves the GP1 subunit of GP (Chandran et al., 2005; 
Schornberg et al., 2006). To address the possibility that our compounds target this step, 
we measured cathepsin B activity in the presence of the anti-EboV compounds and 
found no effect in vitro or in cells (data not shown). Moreover, all of the compounds 
tested still inhibited infection by VSV EboV particles pre-cleaved with thermolysin (THL), 
a metalloprotease that faithfully mimics cathepsin cleavage of the GP1 subunit of GP 
(Figure 2-4a,b) (Schornberg et al., 2006; Wong et al., 2010). Furthermore, much like 
untreated virus, pre-incubation of THL-treated virus particles with the anti-EboV 
compounds did not reduce infectivity (Figure 2-4c). These findings demonstrate that the 
target of the antiviral compounds is neither cathepsin B nor a CatB-dependent GP 
intermediate. 
 
E. Chemical properties of EboV inhibitors 
In an attempt to identify the potential targets of our compounds, we examined the 
physiochemical and structural properties of the “hits” from screening libraries of existing 
drugs and small-molecules. We noticed that many of the hits of the anti-EboV bioactives 
screen, including alverine, tamoxifen, setraline and U18666A, are cationic amphiphiles 
(Table 2-2). Although cationic amphiphilic drugs (CADs) are a structurally and 
functionally diverse group of compounds, they each contain a hydrophobic ring attached 
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† IC50 and IC90 values were estimated from dose response curves as described for Table 2-1. 
Virus infection was graphed as a percent relative to cells exposed to DMSO vehicle alone and 
IC values were estimated from these graphs. Data is representative of three independent 
experiments. N=6. 
Table 2-2. Bioactive CAD-like compounds that inhibit EboV GP entry 
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Figure 2-5. Predicted physiochemical properties of compounds that inhibit EboV entry. A 
comparison of the calculated relative lipophilicity, represented here as the log of the partition constant 
(clogP), versus the calculated relative acidity, represented as the log of the acid dissociation constant 
(pKa) for the EboV entry inhibitors identified through the bioactive (red) and small molecule screens 
(gray scale). The physiochemical properties were calculated using the Virtual Computational 
Chemistry Laboratory, VCCLAB (http://www.vcclab.org; Tetko et al., 2005). The clogP values are the 
average of several different methods of calculating the clogP ± s.d. Where available, experimentally 
observed logP and pKa were plotted. Dotted lines represent the minimal clogP (>3.0) and pKa (>8.5) 
values required for CAD like activity.   
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 to a hydrophilic side chain (clog P>3.0) that contains a basic amine (pKa>8.5) 
(Kodavanti and Mehendale, 1990; Kornhuber et al., 2008; Hanumegowda et al., 2010). 
To examine the possible relationship between these parameters and antiviral activity, 
the clogP and pKa of each compound were calculated and plotted (Fig 2-5). We 
observed that 4.0, 5.0 and 5.10 met the criteria to be classified as cationic amphiphiles 
while 3.0, 3.47, 6.0 and 7.0 did not.  
 
F. Antiviral compounds 3.0 and 3.47 induce cytoplasmic cholesterol accumulation 
 Previous studies of CADs indicate that many accumulate in LE/LYs and inhibit 
degradation of phospholipids, sphingomyelin and cholesterol (Matsuzawa and Hostetler, 
1980; Yoshikawa, 1991; Kobayashi et al., 1999; Makino et al., 2006; Sawada et al., 
2005; Sobo et al., 2007). To see whether the antiviral compounds function like CADs, 
we treated Vero cells with the compounds and after 24 hours, fixed and stained the cells 
with the cholesterol-avid fluorophore filipin. As expected, we observed that the CADs 
tamoxifen and U18666A induced accumulation of filipin-positive vesicles in the 
perinuclear region of cells. Interestingly, we observed accumulation of filipin-positive 
cytoplasmic vacuoles in cells treated with inhibitors 3.0 and 3.47, although not in cells 
treated with 4.0, 5.0, 5.10, 6.0, 7.0, 8.0 or E64d (Figure 2-6). Compounds 3.0 and 3.47 
also induced cholesterol-positive vacuoles in HeLa (Figure 2-10a) and CHO-K1 cells as 
well as primary human fibroblasts. These filipin-positive vacuoles were induced by 
compounds 3.0 and 3.47 in a dose-dependent manner, which correlated with their 
antiviral activities. Notably, 3.0 and 3.47 are significantly less basic and hydrophobic 
than the other anti-EboV compounds, as well as the well-characterized CADs,  
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Figure 2-6. Compounds 3.0 and 3.47 lead to cholesterol accumulation in cells. Vero cells were 
treated with vehicle (DMSO), 3.0 (20 µM), 3.47 (10 µM), 4.0 (20 µM), 5.0 (20 µM), 5.10 (10 µM), 6.0 
(20 µM), 7.0 (20 µM), 8.0 (20 µM), the cystine protease inhibitor E64d (30µM), tamoxifen (Tamox, 
10µM), or U18666A (U18, 20µM)  for 18 h. then fixed and incubated with the cholesterol-avid 
fluorophore filipin. The cationic amphiphilic drugs tamoxifen and U18666A served as positive controls 
for cholesterol accumulation in these experiments. 
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suggesting these properties are not strict predictors of cholesterol accumulating activity. 
 
G. Cholesterol uptake pathway 
 To determine the origin of the filipin stained vacuoles, cells treated with 3.0 and 
3.47 were analyzed using membrane-compartment specific antibodies. We observed 
that filipin-positive vacuoles were also positive for the LE/LY-specific lipid 
bis(monoacylglycerol)phosphate (BMP) and also for LysoTracker (data not shown). The 
induction of filipin-stained LE/LY membranes by 3.0 and 3.47 suggested that they might 
target one or more proteins involved in regulation of cholesterol uptake in the LE/LY of 
cells. Dietary cholesterol is normally taken up by the cell in low-density lipoproteins 
(LDL) through binding and endocytosis of LDL receptors (LDLR). The lipoproteins are 
then cleaved within the LE/LY, and the released cholesterol esters are hydrolyzed and 
transported across the limiting membrane into the cytoplasm (Brown and Goldstein, 
1986). This transport of cholesterol from LDL to the cytoplasm is dependent on a 
complex mechanism involving carrier protein Niemann-Pick C2 and formation of specific 
lipid microdomains mediated by ALG-2-interacting protein X (Alix), acid 
sphingomyelinase (ASM), and BMP (Chevallier et al., 2008; Devlin et al., 2010). NPC2 
then transfers the cholesterol to NPC1, a multi-pass cholesterol transport protein in the 
limiting membrane of the LE/LY (Kwon et al., 2009), which facilitates cholesterol export 
from the late endosome through an intracellular interaction with oxysterol binding 
protein-like 5 (ORP5), which may help transport cholesterol from NPC1 to the ER (Du et 
al, 2011). Disruption of any of the components in this highly regulated pathway results in 
accumulation of LDL cholesterol and other lipids in the LE/LY (Reaves et al., 2000; 
! '*!
Leventhal et al., 2001; Chevallier et al., 2008). 
 
H. NPC1 is an essential host factor for EboV entry 
 To test the hypothesis that the target of 3.0 and 3.47 might be a protein essential 
for the uptake of cholesterol in the late endosome compartment, we studied EboV GP 
infection of primary human fibroblasts from patients with genetic lysosomal storage 
disorders affecting the cholesterol uptake pathway. We tested primary human 
fibroblasts from Niemann-Pick disease patients with mutations in the cholesterol 
transport proteins Niemann–Pick C1 (NPC1-(A)), Niemann–Pick C2 (NPC2-), and acid 
sphingomyelinase (ASM-) (Kolter and Sandhoff, 2010). As expected, all three of these 
cell lines contained filipin-positive cytoplasmic vacuoles (Figure 2-7a and 2-8a). 
Remarkably, we found that only the fibroblasts from the patient with mutations in NPC1, 
but not those in NPC2 or ASM, were highly resistant to EboV GP infection (Figure 2-7b, 
Figure 2-8b). Interestingly, in contrast to the two-log decrease in EboV GP-dependent 
infection in NPC1-(A) cells, we only observed a two-fold defect in EboV GP mediated 
infection upon infection of a second source of NPC1 mutant cells from a different patient 
(NPC1-(B)) (Figure 2-8 a,b). This difference was likely explained by the specific effects 
caused by the mutations in each sample; NPC-(A) cells expressed low levels of NPC1 
in the LE/LY (Gelsthorpe et al., 2008), while NPC-(B) cells abundantly expressed a 
gene product with a single missense mutation disrupting its cholesterol transport activity 
(Blom et al., 2003). 
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Figure 2-7. Cells from patients with Niemann-Pick type C1 are resistant to EboV GP infection. 
(a) Human fibroblast cell lines derived from patients with Niemann-Pick type C1 or C2 disease were 
analyzed for cytoplasmic cholesterol deposits using filipin staining. (Coreill, GM17914) (NPC1-) is a 
compound heterozygote with a frameshift and a missense mutation (I106T) that results in a 
misfolding; GM18429 (NPC2-) is homozygous for a substitution that results in defective splicing of 
NPC2 RNA; and GM05659 (wt) fibroblasts are from a healthy human donor. Representative images 
are shown. (b) Wt, NPC1-, and NPC2- fibroblasts were exposed to VSV particles pseudotyped with 
VSV G, LFV GP or EboV GP. Virus infection is reported as percent of luminescence units (RLU) on wt 
cells. Data is mean ± s.d. (n=3) and is representative of 3 experiments.  
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Figure 2-8. Comparison of EboV GP infection on two different NPC1- mutant fibroblasts.   (a) 
Human fibroblast cell lines derived from patients with Niemann-Pick disease caused by mutations in 
acid sphingomyelinase (ASM-), Niemann–Pick C2 (NPC2-), and two different mutations in Niemann-
Pick C1 (NPC1-(A) or NPC-1(B)) were analyzed for cholesterol accumulation using filipin staining. 
Both NPC1- cells are compound heterozygotes with one allele that has a missense mutation (I106T) 
that results in a misfolding and degradation of NPC1. In NPC1-(A) (GM17914, Coreill) the second 
allele has a 2bp insertion that leads to a premature stop codon. In NPC1-(B) (GM03123, Coreill) the 
second allele has a missense mutation (P237S) in which NPC1 traffics to late endosomes, but is 
defective in cholesterol transport function. NPC2- (GM18429, Coreill) is described in Figure 2-7. 
ASM- (GM16195, Coreill) is homozygous for a missense mutation (L302P) that results in defective 
enzyme function. Representative images are shown. (b) Fibroblasts were exposed to VSV GFP 
particles pseudotyped with EboV GP. Virus infection is reported as percent GFP-positive cells relative 
to NPC2- control. Data are mean ± s.d. (n=3) 
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These findings suggest that NPC1 protein is specifically required for infection. 
We further tested this conclusion by infecting cells systematically disrupted in the other 
cellular factors involved in the LDL derived cholesterol uptake pathway (Kolter and 
Sandhoff, 2010; Ko et al., 2001; Du et al., 2011; Chevallier et al., 2008). To determine if 
BMP is required, infectivity was assessed in cells treated with a well-characterized 
antibody to BMP (Kobayashi et al., 1999; Le Blanc et al., 2005). Vero cells incubated 
overnight with 5 or 50 µg/ml of either #-BMP or mouse IgG isotype control (mIgG) 
antibody showed little appreciable difference in EboV GP mediated infectivity under 
conditions that lead to more than a two-fold reduction in VSV G infectivity (Figure 2-9). 
We further studied the roles of the known host proteins involved in cholesterol uptake by 
assessing the effects of siRNA knockdown of their expression on EboV GP-dependent 
infection. We confirmed that EboV GP-dependent infection required expression of 
NPC1, but did not observe a comparable effect upon knockdown of NPC2, ASM, Alix, or 
ORP5 under these conditions (Figure 2-10 b,c).  
In order to more rigorously test the role of NPC1 during EboV infection, we 
studied a set of Chinese hamster ovary (CHO)-derived cell lines in which expression of 
endogenous NPC1 had been knocked out. We found that the titer of a murine leukemia 
virus (MLV) vector pseudotyped with EboV GP on wild-type CHO cells (CHOwt) 
exceeded 106 infectious units per ml (Fig. 2-11 a,b), while CHO cells lacking NPC1 
(CHOnull) were completely resistant to infection. Importantly, infection of these cells was 
fully restored when NPC1 was exogenously expressed (CHONPC1), indicating that NPC1 
expression is indeed essential for EboV infection. 
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Figure 2-9. A BMP antibody does not inhibit EboV GP entry. Vero cells were plated in a 96-well 
plate and incubated with 5 or 50 µg/ml of an antibody directed against BMP or a !"#$%&!"'"()"'*)&+,-&
.$"/01%& ("'/2")& 3!+,-4. After 24 hours, the cells were infected VSV particles encoding GFP 
pseudotyped with either EboV GP (black bars), VSV G (white open bars) or Junin GP (gray bars). 
Virus infection is reported as percent of GFP-positive cells relative to cells exposed to the isotype 
control antibody. Data are mean ± s.d. (n=3). 
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Figure 2-10. NPC1 is essential for Ebola virus infection. (a) HeLa cells were treated with 3.0 (20 
µM), 3.47 (1.25 µM) or vehicle for 18 h, then fixed and incubated with the cholesterol-avid fluorophore 
filipin. (b,c) Expression of NPC1, NPC2, ASM, Alix, acid ceramidase (AC) and ORP5 was knocked-
down in HeLa cells using SMARTpool siRNA (20 nM, Dharmacon). After 72 hours, cells were 
assessed for infection or protein expression. (b) Protein expression was measured by immunoblot of 
cell lysates using anti-ASM 1H7 (Genzyme), anti-NPC1 (Abcam), anti-AC (BD Biosciences), anti-Alix 
(Biolegend), and anti-ORP5 (Abcam). (c) HeLa cells were transfected with siRNAs targeting Alix, 
ASM, NPC1, NPC2 and ORP5. After 72 h, VSV-EboV-GP or LFV-GP infection of these cells was 
measured as in Fig. 2-7b. Data are mean ± s.d. (n=3) and is representative of three experiments. 
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CHOnull cells have enlarged LE/LY that contain excess cholesterol and sphingolipids
 
(Millard et al., 2005). To determine if EboV infection is inhibited by endosome 
dysfunction secondary to the absence of NPC1, we studied a well-characterized sterol-
sensing domain mutant P692S that is defective in cholesterol uptake and NPC1-
dependent membrane trafficking but not expression or localization (Ko et al., 2001; 
Millard et al., 2005; Ohgami et al., 2004). We found that expression of NPC1 P692S 
fully supports infection of CHOnull cells (Fig. 2-11 a,b). Conversely, mutants NPC1 
L657F and NPC1 D787N, which exhibit increased rates of cholesterol transport (Millard 
et al., 2005), did not enhance EboV GP infection. Thus, consistent with what we 
previously observed with human NPC1-(A) and NPC1-(B) cells, EboV entry is strictly 
dependent on NPC1 expression, but not on NPC1-dependent cholesterol transport 
activity. Consistent with the conclusion that NPC1 expression is essential for EboV GP-
dependent entry, we found that replication competent Ebola virus could not grow on 
CHOnull cells (Fig. 2-11c). The requirement for NPC1 was found to exist for all known 
filoviruses, as single-round infection by MLV particles bearing GPs from the filovirus 
species Marburg marburgvirus (MarV), Sudan ebolavirus (SudV), Taï Forest ebolavirus 
(TaFV), Reston ebolavirus (RestV) and Bundibugyo ebolavirus (BdbV) were all strictly 
dependent on NPC1 expression (Table 2-3). As these viruses are not closely related 
(Towner et al., 2008), these findings suggest that the requirement for NPC1 as an entry 
factor has been conserved through evolution of the Filoviridae family. 
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Figure 2-11. Presence of NPC1 protein but not cholesterol transport function is essential for 
Ebola virus infection. (a) Phenotype of cells expressing NPC1 mutant proteins. CHOwt, CHOnull, and 
CHOnull cells stably expressing wild type mouse NPC1 or NPC1 mutants L657F, P692S, D787N were 
fixed and stained with filipin, and representative images are shown. (b) These CHO cell lines were 
exposed to MLV particles encoding LacZ and pseudotyped with either EboV GP or VSV G. Results 
are the mean ± s.d. (n=4) and is representative of three experiments. FFU, focus forming units. (c) 
CHOwt, CHOnull, and CHONPC1 cells were infected with replication competent Ebola virus Zaire-
Mayinga encoding GFP (m.o.i.=1). Results are mean relative fluorescence units ± s.d. (n=3).  
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 I. Cathepsin B and NPC1 mediate distinct steps during EboV entry 
Since NPC1 and cathepsin B are both essential host factors, we analyzed their 
relationship during infection. We found that treatment of cells with the cathepsin inhibitor 
E64d at concentrations that blocked infection did not induce cholesterol accumulation 
(Figure 2-6, bottom left). Additionally, we tested the possibility that disruption of NPC1 
could interfere with the protease activity of cathepsin B. In our initial experiment, we 
measured cathepsin B activity in CHOnull cells and found that it was not significantly 
different from CHOwt cells (Figure 2-12a). To determine if NPC1 is required for virus 
processing by cathepsin B, we tested whether thermolysin-cleaved particles were 
dependent on NPC1. As expected, we found that thermolysin-cleaved particles are 
infectious and resistant to inactivation of cathepsin B when NPC1 is present (Figure 2-
12b). However, thermolysin cleavage did not bypass the barrier to virus infection in 
NPC1 deficient cells. Taken together, these findings indicate that cathepsin B and 
NPC1 mediate distinct steps in infection. 
J. Protease-cleaved EboV GP binds NPC1 
Previous studies suggest that the product of cathepsin B cleavage of the GP1 subunit of 
EboV GP is a ligand for a host factor (Kuhn et al., 2006; Kaletsky et al., 2007; Brindley 
et al., 2007; and Dube et al., 2009 and 2010). To determine if NPC1 is this host factor, 
we performed a series of experiments measuring binding of EboV GP to LE/LY 
membranes from CHOnull, CHONPC1 and CHOP692S cells (Figure 2-13 a, b left panel). 
EboV GP was prepared in the form of a purified recombinant protein that is truncated 
! (*!
 
Figure 2-12. Cathepsin B and NPC1 mediate distinct steps during EboV entry.  (a) The 
relationship between NPC1 expression and cathepsin B activity in CHO cells. CHOwt and CHOnull cells 
were incubated in medium containing the Cat B inhibitor CA074 (80 µM) or vehicle (1% DMSO) for 4 
hours, and Cat B protease activity was measured in cell lysates using a fluorogenic substrate. Cat B 
activity (V0, relative fluorescence units (RFU)/sec) is plotted. Results are mean ± s.d. (n=9). (b) 
CHOwt and CHOnull cells were treated with the cathepsin B inhibitor CA074 (80 µM) or vehicle. These 
cells were challenged with VSV G particles or VSV EboV GP particles treated with thermolysin (EboV 
GPTHL) or untreated control (EboV GP). Infection was measured as in Fig. 2-9. Data are mean ± s.d. 
(n=9). 
a b 
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Figure 2-13. Protease-cleaved EboV GP binds to NPC1 containing membranes. (a) Schematic 
diagram of EboV GP1 binding assay used in panel (c and d).  (b) Left, LE/LY membranes from 
CHONPC1,CHOnull and CHO NPC1 P692S cells were analyzed by immunoblot using antibodies to 
NPC1 or V-ATPase B1/2. Right, VSV EboV GP particles and EboV GP
!TM protein were incubated in 
the presence or absence of thermolysin (THL) and analyzed by immunoblot for GP1. (c) EboV GP
!TM 
or thermolysin-cleaved EboV GP
!TM (0.1, 0.5, or 1.0 µg) was added to LE/LY membranes purified 
from CHOnull or CHONPC1 cells. Membrane bound and unbound GP1 were analyzed by immunoblot. 
(d) Thermolysin-cleaved EboV  GP
!TM binds to membranes containing the NPC1 mutant P692S. 
Thermolysin-cleaved EboV GP
!TM protein (1 µg) was added to LE/LY membranes from CHOnull, 
CHONPC1, or CHO NPC1 P692S cells and analyzed as in (c). 
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d 
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just before the transmembrane domain (EboV GP$TM). EboV GP$TM is a trimer that is 
faithfully cleaved by thermolysin (Figure 2-13 b right panel). We found that binding of 
EboV GP$TM to LE/LY membranes is concentration dependent, saturable, and strictly 
dependent on both thermolysin cleavage of GP1 and membrane expression of NPC1 or 
NPC1 P692S (Figure 2-13 c,d; 2-14a). We performed a co-immunoprecipitation 
experiment to determine whether cleaved GP binds to NPC1. LE/LY membranes were 
incubated with EboV GP$TM and then solubilized in detergent. NPC1 was recovered 
from the lysate by immunoprecipitation and the immune complexes were fractionated on 
a polyacrylamide gel, and analyzed for the presence of GP1. We found cleaved EboV 
GP$TM, but not uncleaved EboV GP$TM  bound to and co-immunoprecipitated with NPC1 
(Figure 2-14b). These results suggest that cathepsins act upstream of the NPC1 binding 
step, and may serve to unmask a NPC1 binding domain present within EboV GP. 
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Figure 2-14. Protease-cleaved EboV GP binds to NPC1. (a) LE/LY membranes from CHONPC1 were 
incubated with increasing concentrations of thermolysin cleaved EboV GP
!TM as in Figure 2-13. GP1 
was analyzed in membrane bound and supernatant fractions using immunoblot (top). Densitometry 
was performed and the relative intensity of each GP1 band was measured using Quantity One 
Software (Bio-Rad). The data was used to plot the amount of GP1 in the supernatant and the amount 
bound to LE/LY membranes as a function of the input concentration of EboV GP
!TM. (b) LE/LY 
membranes from CHOnull or CHOhNPC1 cells were incubated with EboV GP!TM or thermolysin cleaved 
EboV GP
!TM. Following binding, membranes were dissolved in the detergent CHAPSO, NPC1 was 
precipitated using an NPC1-specific antibody, and the immunoprecipitate and the input membrane 
lysate were analyzed by immunoblot for NPC1 (top) or GP1 (bottom). * IgG heavy chain. 
a 
b 
a 
b 
 
 
a 
b b 
THL 
* 
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Bound 
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Discussion: 
 Although numerous host factors responsible for the initial steps of EboV entry 
have been proposed, including attachment, uptake, and priming through GP proteolysis, 
the identities of the host-factors responsible for the later steps that are directly 
responsible for triggering fusion within the LE/LY have remained a major unknown facet 
of the EboV entry mechanism. Indeed, the latest understood step, that of endosomal 
cathepsin-mediated proteolysis of GP1, has demonstrated that EboV particles are not 
infectious until the heavily glycosylated exterior subdomains are removed. The domain 
of GP1 exposed by cathepsin cleavage has been previously proposed to be a binding 
site for an unidentified host factor required for, or immediately preceding triggering of 
the fusion protein. Unfortunately, repeated biochemical attempts have not been able to 
fish out the hypothesized binding partner for this ligand. 
Experiments investigating the antiviral mechanisms of a series of small molecule 
EboV entry inhibitors lead us to investigate the possible role for components of the 
LE/LY cholesterol processing pathway in EboV entry. One of the integral components of 
this pathway, the multi-spanning protein NPC1, was found to be an essential factor in 
EboV infection as well. Although drug-induced defects originally informed our 
investigations into the potential roles of NPC1 and the other cholesterol transport 
components, our subsequent experiments showed that the requirement for NPC1 in 
EboV entry was actually quite distinct from this process; neither disruption of the other 
essential components of the cholesterol transport pathway, such as NPC2 or ORP5, nor 
infection of cells encoding missense mutations of NPC1 specifically perturbing the rate 
of cholesterol transport, had a significant effect on the outcome of EboV GP-dependent 
! )"!
infection. Instead, the physical availability of NPC1 within LE/LY appeared critical, as 
neither hamster cells with complete deletions of NPC1, nor human cells containing 
misfolded and thus prematurely degraded NPC1, were able to support EboV GP-
dependent infection. 
Critically, our experiments returned to where the aforementioned in vitro 
biochemical experiments had left off (Chandran et al., 2005; Schornberg et al., 2006; 
Dube et al., 2009), as we were able to demonstrate that EboV GP is capable of binding 
NPC1, using either an NPC1-containing membrane binding ELISA, or a more specific 
co-immunoprecipitation assay. Furthermore, our data supported a post-cathepsin 
cleavage binding event, as soluble EboV GP trimers processed in vitro using 
thermolysin were capable of binding NPC1, while unprocessed GP was not. These 
results support a model wherein cathepsin proteases, active in the low pH environment 
of the LE/LY, serve to unmask the RBDs present on the EboV GP timers extending from 
the viral particles. Binding of the exposed RBDs to NPC1 present on the limiting 
membrane of the LE/LY is able to provide a crucial step for triggering EboV GP to fuse. 
Though yet to be proven, it is quite possible that GP1 binding to NPC1 may be 
sufficient to trigger the conformational changes in the EboV GP that essentially begin 
the membrane fusion cascade. Analysis of the EboV GP structure reveals that the 
residues in the N-terminal domain of GP1 that likely mediate binding to NPC1 are 
interspersed with the residues that make stabilizing contacts with GP2 (Lee et al, 2008). 
Thus, binding of cleaved GP1 to NPC1 may relieve the GP1-imposed constraints on 
GP2 and that prevent fusion peptide insertion into the limiting membrane of the LE/LY 
(Figure 2-15). According to this model, the role of to expose the NPC1 binding site 
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Figure 2-15. Revised model of EBOV entry. EBOV particles bind to attachment factors on the cell 
surface and are internalized by macropinocytosis. EBOV GP is cleaved by endosomal cysteine 
proteases exposing the receptor binding domain, which is a ligand for NPC1.  
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during EboV infection would be analogous to the role of CD4 in inducing a 
conformational change in gp120 to expose the co-receptor binding site during HIV 
infection, while NPC1 would serve as the CCR5 or CXCR4 co-receptor triggers 
(Harrison, 2008). An alternative possibility is that binding of protease-cleaved GP1 to 
NPC1 is an essential step in infection, but virus membrane fusion is not triggered until 
an additional signal is received. This may include further cleavage of GP by cathepsin 
proteases, as has been previously proposed based on the yet explained existence of a 
post-cathepsin B E64 sensitive step (Chandran et al, 2005; Schornberg et al, 2006; 
Wong et al, 2010), or a yet unidentified step, which may or may not require the low pH 
of the LE/LY. Lastly, these studies provide a successful example of how small 
molecules identified by screening and optimized by medicinal chemistry, can be used to 
identify novel virus-host interactions. 
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Chapter 3 
 
Using small molecule inhibitors to probe the role of NPC1 in Ebola virus entry 
 
The data presented in this chapter is derived in part from the following published work. 
 
 
Côté M.*, Misasi J.*, Ren T.*, Bruchez A.*, Lee K., Filone C.M., Hensley L., Li Q., Ory D., 
Chandran K., Cunningham J. Small molecule inhibitors reveal Niemann–Pick C1 is 
essential for Ebola virus infection. Nature. 447, 344-348 (2011). 
*Contributed equally. 
 
Author Contributions:  KL synthesized and purified 3.0 analogs and AB tested them. 
AB carried out infection assays with pseudotyped viruses, performed microscopy, and 
executed NPC1 overexpression studies. AB designed and performed resistant virus 
studies.  JM purified recombinant glycoprotein. MC and JM designed and performed 
binding assays. MC performed crosslinking and click chemsitry. Ebola virus infections 
were performed in the lab of LH by CF.!!
 
Figure contributions: MC produced the data for Figures 3-1d, 3-2, and 3-3. CF 
produced the data for Figure 3-1c. JM produced the data for Figure 3-6. AB produced all 
other Figures.
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Abstract!
 Filoviruses, including Ebola virus (EboV) and Marburg virus, are a family of 
enveloped negative stranded RNA viruses that are known to cause highly lethal 
haemorrhagic fever in primates. Despite the fact that these viruses are considered an 
emerging health risk, due in large part to the increasing frequency of outbreaks and the 
high morbidity and mortality rates of these infections, currently no effective vaccine or 
antiviral therapeutics exist and patient care is limited to palliative measures. We have 
recently reported that a small molecule inhibitor of EboV entry, 3.0, lead us to the 
discovery of an essential host factor for filovirus entry, the cholesterol transporter 
Niemann-Pick C1 (NPC1). Here we describe the follow-up inhibitor based studies that 
probe how 3.0 and its derivatives prevent EboV entry into host cells by interacting with 
NPC1. A derivative of 3.0 that lacked the tertiary amine, which is unable to become 
protonated in the late endosome of cells, remained as active as the 3.0 parent 
compound. This suggests that the compounds do not rely on a charge base mechanism 
for activity. A photo-affinity labeled derivative of 3.0 cross-linked to NPC1 and active 
derivatives blocked binding of post-cathepsin cleaved EboV-GP to NPC1 containing 
membranes. Overexpression of NPC1 rendered cells resistant to EboV inhibition by 3.0 
and its potent derivative 3.47. These findings indicate that the 3.0 series of compounds 
bind to NPC1 and, as a result, interfere with a functionally significant interaction 
between GP1 and NPC1.  Furthermore, mutations that confer sensitivity or resistance to 
the inhibitors lay within the previously identified receptor binding domain (RBD) of GP1 
and are exposed only after cathepsin mediated cleavage. This is consistent with 
previous findings that GP binds to NPC1 only after protease cleavage. Taken together, 
! "$!
this data suggests that the small molecule inhibitors interact directly with NPC1 in a way 
that interferes with the virus-receptor interaction of the post-cathepsin cleaved GP1 to 
NPC1. 
 
Introduction 
 In Chapter 2 we established that NPC1 was an essential host factor for EboV 
entry. This finding was corroborated by a publication from another group that identified 
NPC1 through the use of a haploid genetic screen (Carette et al., 2011). Both studies 
found that NPC1 was essential for EboV GP mediated entry as well as infection with 
replication competent EboV, and that differences in NPC1 expression did not affect the 
entry of other viruses, including other low pH dependent viruses. Carette et al. saw that 
in NPC1 null cells, entry of VSV pseudotyped with EboV-GP was arrested at a late 
stage in virus entry, and that virions seemed to accumulate in the late endosome/ 
lysosome (LE/LY) of these cells (2011). Consistent with this finding, we found that only 
post-cathepsin cleaved GP could bind to NPC1 containing membranes, suggesting that 
binding takes place only after cathepsin cleavage has occurred in the late endosome 
and lysosome of cells. Furthermore, both studies found that disruption of NPC2 
expression did not impact EboV infectivity, indicating that cholesterol misregulation itself 
is not the root cause of defective EboV entry in NPC1 null cells. Additionally, we found 
that knockdown of additional factors involved in the cholesterol uptake pathway had no 
appreciable negative effects upon EboV entry. Indeed, the eventual discrepancy 
between cholesterol transport and EboV entry phenotype became most obvious upon 
testing cells harboring various NPC1 missense mutations, which exhibited either 
! "%!
enhanced or greatly reduced cholesterol transport activity, but supported levels of EboV 
entry comparable to WT cells. These results supported the interpretation that the 
physical presence of the NPC1 protein in the LE/LY was the requirement for EboV 
entry. Subsequent experiments found that NPC1 is capable of binding the post-
cathepsin EboV GP, suggesting that it may provide a receptor-like role in entry. Still, 
additional structural and functional studies are required to more rigorously characterize 
the manner in which NPC1 functions during EboV entry. We decided to take advantage 
of our newly identified EboV inhibitor 3.0, along with its informative derivatives, by 
incorporating them in additional biochemical, functional, and genetic assays to further 
understand the interaction between EboV GP and NPC1. 
 
Results  
A. Informative derivatives of EboV inhibitor 3.0 
 In Chapter 2 we described the identification of 3.0, a novel benzylpiperazine 
adamantane diamide-derived compound, by a high-throughput screen of a small 
molecule library for EboV entry inhibitors. We subsequently developed a subset of 
3.0 derivatives through a series of structure activity relationship (SAR) studies, which 
carried a distinct set of structural and functional characteristics that could be utilized 
in additional biochemical and functional assays. Of the greater than 50 analogs of 3.0 
that were synthesized and tested, we selected a set of four derivatives with varying 
potency and physiochemical properties that could serve as particularly informative 
probes in our assays. A number of derivatives were less potent against EboV GP-
dependent infection; in the case of compound 3.18, which has an additional carbon  
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Figure 3-1 (Continued). Structure and function of 3.0 derived EboV entry inhibitors. (a) 
Compounds 3.0 and informative derivatives 3.0 (-) amine, 3.18, 3.47, and 3.98 . (b) Vero cells were 
grown in media containing increasing concentrations of 3.0, 3.0 (-) amine, 3.18, 3.47, or 3.98 for 90 
min before the addition of VSV particles encoding luciferase (3.18, 3.47, 3.98) or GFP (3.0, 3.0 (-) 
amine) and pseudotyped with EboV GP. Virus infection is reported as percent of luminescence units 
(RLU) or GFP-positive cells relative to cells exposed to DMSO vehicle alone. Data are mean ± s.d. 
(n=4) and is representative of three experiments. (c) Vero cells were grown in media containing 3.0 
(40 µM), 3.47 (40 µM), vehicle (1% DMSO) or the cysteine cathepsin protease inhibitor E-64d (150 
µM) 90 min before the addition of replication competent Ebola virus Zaire-Mayinga encoding GFP 
(multiplicity of infection (m.o.i.)=0.1). Results are mean relative fluorescence units (RFU) ± s.e.m. 
(n=3). (d) Cells treated with 3.0 derived EboV inhibitors develop cholesterol filled intracellular 
vesicles characteristic of NPC phenotype. HeLa cells treated overnight with 2.5µM of the indicated 
inhibitor were stained with the cholesterol-avid dye filipin.  
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inserted into the diamide backbone, the IC50 was more than 10-fold higher than 
parent compound 3.0 (Figure 3-1 a,b). More potent derivatives were identified as 
well; as described in chapter 2, the addition of a (methoxycarbonyl) benzyl group at 
the ortho position of the benzene ring yielded compound 3.47, which exhibited a 
greater than 10-fold decrease in the IC50 as compared to parent compound 3.0 
(Figure 3-1 a,b). The increased potency of 3.47 was particularly evident in 
experiments measuring the growth of replication competent EboV on Vero cells, 
where 3.47 was able to reduce infection to the level of the cathepsin inhibitor E64d, a 
well characterized inhibitor of EboV replication (Chandran et al., 2005). In contrast, 
an equal concentration of 3.0 reduced infection less than 2-fold from the vehicle 
negative control (Figure 3-1 c). These findings suggest that subtle changes in the 
structure of 3.0 can have a profound impact on the antiviral activity of the compound. 
 Given that changes to the structure of 3.0 can impact the antiviral activity of 
the compound, we sought to investigate whether changes to the physiochemical 
properties of 3.0 could have similar impacts on antiviral activity. In Chapter 2, we 
initially tested whether our compounds could induce cellular cholesterol accumulation 
since several of them had CAD like physiochemical properties. A central component 
of drug-induced phospholipidosis is protonation of the compounds within the 
lysosomes, which results in the trapping and subsequent accumulation of compound-
phospholipid complexes in the lumenal membranes of the late endosome and 
lysosome (Kodavanti and Mehendale, 1990; Anderson and Borlak, 2006; Alakoskela 
et al., 2009; Hanumegowda et al., 2010). This accumulation results in the eventual 
disruption of lipid, cholesterol, and protein regulation in the late endosome 
! $)!
(Kobayashi et al., 1999; Alpy et al., 2001; Kobayashi et al., 2001; Makino et al., 2006; 
Sobo et al., 2007; Chevallier et al., 2008). As noted in Chapter 2, both 3.0 and 3.47 
have relatively low pKa values (~6.0) when compared to known CAD compounds, 
which traditionally have pKa values of >8.5 (Kornhuber et al., 2008). Thus, both 3.0 
and 3.47 would remain uncharged at neutral pH, unlike CADs whose major species 
at this pH would have a positive charge. However, in the low pH environment of the 
LE/LY (~pH 5.0) (Schmid et al., 1989), the majority of 3.0 and 3.47 would be 
protonated and would carry a positive charge. Thus, we used SAR to experimentally 
test whether 3.0 may act through a protonation induced lysosomal accumulation 
mechanism similar to well characterized CADs. In order to test if protonation in the 
LE/LY is required for 3.0 function, we tested the antiviral activity of a non-
protonatable derivative, referred to as 3.0 (-) amine. In this derivative the tertiary 
amine, which carries a charge at low pH, is replaced with a carbon. The 3.0 (-) amine 
compound was just as potent as the parent compound (Figure 3-1 a, b), indicating 
that protonation of the tertiary amine is not required for antiviral activity. 
 Since a non-specific, charged based mechanism was not responsible for the 
antiviral activity of 3.0 and because subtle changes in the structure could produce 
large changes in the antiviral activity of the compound, we suspected that the 
compound may have a specific interaction with its target molecule. In order to identify 
the proteins that these compounds may target, we used the information gathered 
from extensive SAR studies to synthesize a tagged 3.47 derivative, 3.98. Compound 
3.98 has anti-EboV activity comparable to 3.47 but contains two additional functional 
moieties: an aryl-azide for photoaffinity labeling of target proteins and an alkyne 
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group for specific labeling by click chemistry to allow for detection of the cross-linked 
target (Figure 3-1 a,b). 
Considering that we were first led to investigate NPC1 because of the build-up of 
LE/LY cholesterol in cells treated with 3.0 or 3.47, we sought to test if the informative 
derivatives of 3.0 retained the ability to induce cholesterol accumulation. To test for 
cholesterol build-up, we treated HeLa cells overnight with each of the 3.0 derivatives 
(2.5 µM) and stained the cells with filipin. Interestingly, the antiviral activities of these 
compounds corresponded with their abilities to induce cholesterol accumulation. When 
cells were treated with 3.18, we observed a level of cholesterol accumulation that was 
comparable to the vehicle-treated negative control (Figure 3-1 d). On the other hand, 
the similar levels of cholesterol accumulation exhibited by cells treated with 3.0 or the 
3.0 (-) amine derivative further suggested that cholesterol accumulation was not 
dependent on a positive charge of the molecule in the LE/LY. Lastly, 3.47 and 3.98 also 
exhibited similar levels of cholesterol accumulation, further indicating that the addition of 
the functional aryl-azide and alkyne groups had little effect on the behavior of 3.47 in 
both infectivity and cell phenotype assays. These results suggested that inhibition of 
cholesterol transport by 3.0 derived compounds may be coincident with the antiviral 
activity of the compounds. Given that NPC1 is the only component of the LE/LY 
cholesterol uptake pathway that mediates infection, we hypothesized that the 
compounds directly target NPC1. 
 
B. Compound 3.98 covalently cross-links with NPC1 
! $+!
Studies of 3.0 derivatives with different antiviral potencies revealed a correlation 
between the antiviral activity of the compound and the effect of the compound on 
cholesterol uptake, suggesting that NPC1 is a direct target of the 3.0 derivatives. As 3.0 
and 3.47 lack the functional moieties necessary for biochemical purification, we relied 
upon the added versatility conferred to derivative 3.98. As described above, compound 
3.98 possesses an aryl-azide for photoaffinity labeling of target proteins and an alkyne 
group for specific labeling by click chemistry for identification of the UV adducts (Ban et 
al., 2010), while retaining full anti-EboV and cholesterol-inducing activities, thus proving 
its validity for study. To analyze the direct binding of 3.98 to targets in membrane 
lysates, membrane extracts were incubated with 3.98 (25µM), exposed to UV light, and 
proteins were solubilized in detergent (Figure 3-2a). UV adducts were covalently bound 
to azide-AlexaFluor488 using click chemistry. Membrane lysates or immunoprecipitated 
NPC1 were analyzed by immunoblot using an antibody to AlexaFlour488 to detect 
proteins crosslinked to the inhibitor and membranes were re-blotted to detect NPC1. A 
number of cellular proteins that covalently linked to 3.98 were observed in both CHOnull 
and CHONPC1 membranes (Figure 3-2b, left). The marked increase in labeling of 
proteins greater than 150 kDa in CHONPC1 correlated with expression of NPC1 (Figure 
3-2b, right). Direct probing of NPC1 recovered by immunoprecipitation (Figure 3-2b, 
bottom right) with AlexaFlour488 antibodies confirmed cross-linking to 3.98 (Figure 3-
2b, bottom left). Taken together, the direct labeling of NPC1 by 3.98 and the ability of 
the 3.0-derived compounds to inhibit EboV GP dependent entry, suggests that NPC1 
binding with the these compounds may disrupt the ability of NPC1 to bind cleaved GP1. 
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Figure 3-2.
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Figure 3-2 (Continued). NPC1 is a direct target of EboV inhibitor 3.98 . (a) Compound 3.98 is a 
derivative of the EboV inhibitor 3.47 that contains a photoactivatable aryl azide to induce the covalent 
linkage of the compound to its targets and an alkyne group for specific labeling by click chemistry 
using azide-AlexaFluor488 for protein analysis of UV-adducts. (b) For analysis of the direct binding of 
the EboV compound to NPC1, membrane extracts were incubated with 3.98, exposed to UV light and 
proteins were solubilized in detergent. Cross-linked compound was labeled with azide-AlexaFluor488. 
Total lysates (upper panel) or immunoprecipitated NPC1 from these membrane lysates (lower panel) 
were resolved by SDS-PAGE, transferred to PVDF membranes and proteins cross-linked to 
compound were detected using immunoblot with anti-AlexaFluor488. PVDF membranes were 
reblotted for NPC1. 
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C. Small molecules inhibit binding of EboV GP to NPC1 containing membranes 
Since 3.98, and likely the entire series of 3.0-derived compounds directly bind to 
NPC1, we hypothesized that compound binding to NPC1 may disrupt the ability of 
NPC1 to also bind cleaved EboV GP1. We tested this hypothesis by performing the 
GP1 membrane binding assay described in Chapter 2 (Figure 2-13a) in the presence of 
increasing concentrations of our informative 3.0 derivatives. We first tested the 
relationship between inhibition of binding and antiviral activity by investigating the ability 
of 3.0 derivatives of variable potency to inhibit binding of GP to NPC1 containing 
membranes. We found that 3.0 and 3.47 inhibited binding of cleaved EboV GP!TM to 
NPC1 membranes in a concentration-dependent manner (Figure 3-3a). Importantly, we 
observed a direct correlation between the potency of 3.47, 3.0, and 3.18 in inhibiting 
binding (Figure 3-3a, left panel) and inhibiting infection (Figure 3-1b); 3.47, which is a 
more potent antiviral than 3.0, was capable of disrupting GP1 binding with NPC1 at a 
lower concentration than 3.0, while 3.18, which is vastly less potent than 3.0, was not 
able to disrupt GP1 binding with NPC1 under any of the conditions tested. Notably, the 
3.0 (-) amine derivative also blocked GP1 binding to NPC1 containing membranes in a 
dose dependent manner (Figure 3-3b), confirming that the tertiary amine is dispensable 
for all relevant antiviral activity. We also tested U18666A, a small molecule inhibitor of 
LE/LY cholesterol transport and membrane trafficking (Sobo et al., 2007; Huynh et al., 
2008) and found that it does not inhibit binding of cleaved EboV GP to NPC1 
membranes (Figure 3-3a, right panel). In a third experiment, we compared the ability of 
3.47 and its derivative 3.98, to block binding of GP to NPC1 membranes, and  
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a 
c 
b 
Figure 3-3. Inhibitors act by disrupting GP binding to NPC1 containing membranes. (a) 
Thermolysin-cleaved EboV GP
!TM protein (1µg) was added to LE/LY membranes from CHOnull or 
CHONPC1 cells in the presence of DMSO (10%) or the indicated concentrations of 3.47, 3.0, or 3.18 
(left panel), and 3.47 or U18666A (U18, right panel). Membrane-bound and unbound GP1 were 
analyzed by immunoblot. (b,c) Binding assays were done as in part (a) in the presence of 3.0 derived 
inhibitors (b) or 3.47 and the derivative 3.98 (c). 
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compound 3.98 was capable of blocking GP binding to NPC1 containing membranes to 
similar levels as 3.47 (Figure 3-3c). Taken together, the binding studies establish a 
correlation between the antiviral activity of the compounds and the ability of the 
compounds to inhibit binding of cleaved GP to NPC1 containing membranes.  
These experiments are consistent with a mode of antiviral action for the 3.0 series of 
compounds wherein the drugs bind NPC1 and disrupt its ability to engage cleaved 
EboV GP1 within the LE/LY, preventing the receptor-engagement steps needed for 
EboV GP triggering. We next sought to support this model through additional structural 
and functional studies further detailing the relationships between antiviral activity of the 
compounds and EboV GP1 function. 
  
D. Overexpression of NPC1 confers resistance to inhibitors 
If EboV GP1 binding to NPC1 is an essential step in virus entry, and 3.0-derived 
antiviral compounds are able to limit the proportion of cellular NPC1 capable of 
mediating EboV GP binding, then overexpression of NPC1 could increase the overall 
numbers of inhibitor-free NPC1, and thus the likelihood of an unhindered EboV GP 
entry event in the presence of inhibitors. In order to address this possibility, we 
compared the relationship between inhibitor concentration and relative infectivity on 
CHO cells overexpressing NPC1 (Millard et al., 2000) as compared to cells expressing 
endogenous levels of NPC1 (wt) (Figure 3-4a). Overexpression of NPC1 conferred 
resistance to the antiviral activity of 3.0 and 3.47, with cells overexpressing NPC1 
showing a greater than 30-fold (3.0) or 50-fold (3.47) increase in the IC50 as compared 
to wt cells (Figure 3-4 b). Furthermore, to eliminate the possibility that this 
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Figure 3-4. NPC1 overexpression confers resistance to inhibitors . (a) Left panel. CHOnull, CHOwt, 
CHONPC1, CHOhNPC1 and CHO P692S cells were homogenized, and membranes in the post-nuclear 
supernatant were pelleted at 15000 x g. NPC1 and V-ATPase B1/2 in the pelleted membranes were 
detected by immunoblot. Right panel. CHO cells were infected with VSV-Luc particles pseudotyped 
with EboV GP. Virus infection is reported as relative luminescence units (RLU) (b) CHOwt, CHOhNPC1, 
CHONPC1, and CHO NPC1 P692S cells were incubated in the presence of increasing concentrations 
of 3.0 (left), 3.47 (right) or vehicle prior to the addition of VSV particles pseudotyped with EboV GP. 
Infection was calculated as a percent of the vehicle control. Data is mean ± s.d. (n=4) and is 
representative of 3 experiments.  
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 shift in inhibitor sensitivity is due to cell line variability rather than NPC1 expression, we 
tested several different cell lines stably overexpressing hNPC1, mNPC1 or mNPC1 
P692S (Millard et al., 2000; Millard et al., 2005). We found that all of the overexpression 
cell lines tested exhibited resistance to 3.47, thus minimizing the likelihood that the 
inhibitor shift is due to variability between the cell lines. Importantly, in the absence of 
inhibitor, CHO cells overexpressing hNPC1 exhibited a comparable level of overall 
infectivity when compared to wt CHO cells, while cells overexpressing murine NPC1 or 
NPC1 mutant P692S exhibited mild decreases in infectivity (Figure 3-3a), showing that 
these differences were not caused by inherent increases to EboV GP-mediated 
infectivity in these cells. Additionally, the finding that wt CHO and overexpressing 
hNPC1 CHO cells exhibited no appreciable difference in infectivity suggested that 
endogenous levels of NPC1 expression in CHO cells were not a limiting factor in virus 
entry. These results lend functional support for a model in which binding of 3.0-series 
compounds to NPC1 disrupts EboV GP1 binding to NPC1, making this binding event a 
rate limiting step in the presence of inhibitor, which can be counteracted through greatly 
increased levels of overall NPC1. 
 
E. Inhibitor-resistant viruses suggest target is a receptor-virus interaction 
In Chapter 2, we found that only protease cleaved EboV GP was able to bind 
NPC1 in membrane-binding and co-immunoprecipitation assays, while uncleaved EboV 
GP was not. This finding is consistent with an entry model wherein protease cleavage of 
the GP1 subunit reveals a receptor binding domain (RBD) (Kuhn et al., 2006; Kaletsky 
et al., 2007; Brindley et al., 2007; and Dube et al., 2009 and 2010) that in turn interacts 
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with a host receptor, which we propose is NPC1. Indeed, the actions of the 3.0 derived 
EboV inhibitors, which bind directly to NPC1 and disrupt GP binding to NPC1, suggest 
that they target such a virus-receptor interaction. A classical experiment following small-
molecule inhibition of virus replication is the selection of resistance mutations that 
circumvent the inhibition, and such experiments have previously been used to identify 
mutations that map to the RBD of viral fusion proteins in cases where the small 
molecule inhibitor specifically targets the host receptor to disrupt fusion protein 
interaction (Westby et al., 2007; Tsibris et al., 2008; Ogert et al., 2009). Rather than 
develop an assay where we would passage and hopefully select for virus encoding 
EboV GP mutations capable of circumventing the antiviral effects of the compound, we 
instead decided to look to the naturally occurring sequence variations within various 
filoviridae GPs to identify viruses, and eventually specific coding mutations, that may 
confer resistance to the compounds. Thus, we expanded the studies of the EboV 
inhibitors to include GPs from all known species of filoviruses, which up until this point 
had only been done with GPs from Ebola Zaire. Since all species of filoviruses strictly 
require NPC1 expression for infection (Table 2-3), any resistance to 3.47 would likely be 
due to changes in the way in which GP1 engages NPC1, rather than overall changes in 
NPC1 utilization. 
 
F. Filoviruses Sudan and Marburg are resistant to inhibitors 
We tested the ability of 3.47 to inhibit entry mediated by the GP from each of the 
five species of ebolavirus as well as marburgvirus. We found that Reston ebolavirus (R), 
Tai Forest ebolavirus (T), Bundibugyo ebolavirus (B) and Zaire ebolavirus (Z or EboV)  
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Figure 3-5. Filoviruses Sudan and Marburg are resistant to 3.47.  (a) The effect of increasing 
concentrations of inhibitor 3.47 on infection by VSV luciferase particles pseudotyped with 
glycoproteins from: Marburg marburgvirus (M), Sudan ebolavirus (S), Reston ebolavirus (R), Tai 
Forest ebolavirus (T), Bundibugyo ebolavirus (B) and Zaire ebolavirus (Z). Infectivity was calculated 
as in Figure 3-1b. Data are mean ± s.d. (n=6) and is representative of three experiments. (b) ) A 
percent identity matrix was produced using amino acid sequences of the glycoproteins used in these 
experiments. For all of the Ebola virus species, GPs were used in which the highly variable mucin-like 
domains were deleted and these sequences are compared here. For Marburg virus the full-length GP 
was used in the experiment and is compared to the mucin deleted viruses here. 
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GPs all exhibited a similar level of sensitivity to 3.47 with an IC50 of <1.25 µM. By 
contrast, Sudan ebolavirus (S or SudV) and Marburg marburgvirus (M) GPs were 
resistant to inhibition by 3.47 with an IC50 of >20 µM (Figure 3-5a). Since Zaire and 
Sudan show more sequence conservation (70% identical) in GP than Zaire and 
Marburg (32% identical) (Figure 3-5b), we decided to exploit the differences in 
phenotype between Zaire (EboV) and Sudan (SudV) to map the amino acid 
determinates of inhibitor sensitivity. 
 
G. Compound 3.47 does not inhibit binding of SudV-GP1 to NPC1 membranes  
Recent binding studies from our lab have confirmed that, like EboV GP, binding 
of soluble SudV GP is dependent on both protease cleavage and expression of NPC1 
(Misasi et al., 2012). This finding provided a means by which to further test our 
interpretation that 3.47 antiviral activity is directly related to its ability to disrupt an 
interaction between GP1 and NPC1; since SudV GP is resistant to the antiviral effects 
of 3.47, it may also be capable of binding NPC1 in the presence of high concentrations 
of 3.47 as well. Indeed, when we titrated 3.47 into the membrane-binding assay with 
soluble SudV GP, we found SudV GP1 binding to NPC1-containing membranes was not 
significantly reduced under the same conditions in which EboV GP1 binding was 
reduced by >90% (Figure 3-6). Thus, these results support the interpretation that the 
antiviral activity of 3.0-series of compounds on GP mediated infection directly correlates 
with the abilities of the compounds to inhibit GP binding to NPC1 containing 
membranes.  
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Figure 3-6. Sudan GP1 binding to NPC1 is resistant to EboV Zaire inhibitors. Late endosomal/
lysosomal membranes from cells expressing NPC1 were purified, osmotically lysed and coated on 
ELISA plates. Membranes were treated with indicated concentrations of EboV inhibitor 3.47 prior to 
incubation with a soluble form of EboV GP or SudV GP trimer that had been cleaved with thermolysin 
protease, which faithfully mimics cleavage by endosomal cathepsins to expose the receptor binding 
domain in GP1. After incubation and washing, membranes were solubilized in SDS buffer and the 
presence of bound GP was determined by immunoblot using GP1 antibodies.  
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Figure 3-7. Rec procal exchanges betwee  SudV and EboV G  revealed that the receptor 
binding domain of GP1 conferred sensitivity to 3.47. Virus particles (VSV-eGFP, top panel, or 
ML -LacZ, bottom panels) were ps udotyped with Ps from Sudan and Z ire in which he entirety of 
GP1 or GP2 were swapped, and used to infect Vero cells outright or pre-cleaved by thermolysin (top). 
Once susceptibility was mapped to GP1, additional chimeras were tested to narrow down the 
determinants of drug sensitivity within various GP1 subdomains (bottom). Cells were treated with 20 
µM of compound 3.0 (top) or µM of 3.47 (bottom). Reporter positive cells were cou t d after 
infection. Results are represented as a percentage of the vehicle control (DMSO). 
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H. Resistance to 3.47 maps to amino acids 141 and 142 within the RBD of SudV-
GP  
 Although the SudV and EboV GP proteins are divergent enough to harbor 
contrasting phenotypes to drug sensitivity, they are still conserved enough to be easily 
aligned, providing us the opportunity to further dissect the amino acid requirements 
responsible for inhibitor sensitivity. We began to map the molecular basis for resistance 
by producing viruses pseudotyped with chimeric GPs, in which distinct subdomains of 
the protein were swapped between the Zaire and Sudan sequences, and the 
subsequent viruses were tested for sensitivity to compound 3.47. Initial studies revealed 
that resistance to 3.47 lies within the post-cathepsin cleaved region of SudV-GP1 
(Figure 3-7, top panel). GP1 was further divided into smaller subdomains based on 
existing structural and functional data, including the glycan cap, a cathepsin sensitive 
loop, and the putative minimal RBD (Lee et al., 2010; Dube et al., 2009). Chimeras of 
these functional GP1 domains mapped SudV GP resistance down to the minimal RBD 
of GP1 (Figure 3-7, bottom panel, top half), as the chimeric GPs were resistant to 3.47 
only when the minimal RBD of SudV GP1 was present. Conversely, the minimal RBD of 
EboV GP1 conferred sensitivity to 3.47 when placed in the context of full length SudV 
GP (Figure 3-7, bottom panel, bottom half). The reciprocal nature of this phenotype 
suggested that there was a discrete set of amino acids within the minimal RBD of SudV 
that accounted for resistance to the inhibitor. 
 The minimal RBDs of SudV and EboV are highly conserved at the amino acid 
level (88%) and differ at only eight residues (Figure 3-8a). We compared the atomic 
resolution structures of SudV and EboV GP1 (Lee et al., 2008; Dias et al., 2011; Bale et  
! %%!
Figure 3-8.
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Figure 3-8 (Continued). Reciprocal exchanges at residues 141-142 within the receptor binding 
domain of GP1 conferred sensitivity to 3.47. (a) Sequence alignment for the RBD of EboV GP1 
and SudV GP1. (b) Location of differences between the RBD of SudV GP1 and EboV GP1 on the 
post cathepsin cleaved atomic resolution structures of EboV (left, purple, PDB:3CSY) and SudV 
(right, green, PDB:3S88) GP. (c) MLV particles pseudotyped with chimeric glycoproteins obtained by 
reciprocal exchange of Zaire and Sudan GP sequences were titered on Vero cells. Cells were 
exposed to MLV pseudotypes encoding !-galactosidase. 48 hours post infection, cells were fixed and 
exposed to X-gal to assay for reporter expression. Results are represented as focus forming units 
(FFU) per ml. (d) Vero cells were grown in media containing 3.47 (10µM) for 90 min before the 
addition of MLV-LacZ virus particles pseudotyped with the chimeric glycoproteins. Cells were 
maintained in the presence of 3.47 until reporter positive cells were counted 48 hours after infection. 
Results are represented as a percentage of the vehicle control (DMSO). Data are mean ± s.d. (n=3) 
and is representative of three experiments. “*”: not determined (ND) 
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al., 2012) and identified six clusters of amino acid changes in the RBD (Figure 3-8b). In 
order to test if any of these sequence variations account for the differential inhibition 
phenotypes, we continued to refine our chimeric GPs by performing reciprocal swaps of 
amino acids 98, 124-125, 129, 141-142, 148 and 151 between the two GPs. These 
reciprocal swaps did not significantly change the overall titer of the pseudotyped virus 
particles on Vero cells, thus making it unlikely that any change in sensitivity would be 
due to a secondary effect on virus production (Figure 3-8c). We found that when the 
residues from EboV were placed within the context of the SudV GP, only residues 141-
142 were able to confer sensitivity to 3.47 (Figure 3-8d, right). By contrast, substitutions 
of the other amino acid clusters showed no increase in sensitivity to the inhibitor. When 
the converse exchanges were made in the EboV GP background, a swap at residues 
141-142 made the GP more resistant to 3.47 inhibition (Figure 3-8d, left). Unlike the 
exchange of the other residues in the SudV GP, swapping the remaining residues in 
EboV GP lead to chimeric GPs with intermediate levels of resistance to 3.47, although 
exchange of residues 141-142 still conferred the most pronounced resistance 
phenotype in the EboV GP background. 
These final chimeric GPs, the minimal RBD chimeras, and the parent GPs, were 
subject to a titration of compound 3.47 to further quantitate the extent to which the drug 
sensitivity phenotypes associate with the coding mutations (Figure 3-9). The dose 
response curve for chimeric SudV GPZ141-142 moved to the left, with the IC50 shifting from 
>10µM for SudV GP to <100 nM for SudV GPZ141-142, to a level essentially overlapping 
the IC50 of EboV GP-dependent infection. By contrast, the dose response curve for the 
chimeric EboV GPS141-142 moved to the right, as the IC50 shifted from <100 nM for EboV  
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Figure 3-9. Zaire GP1 RBD Val141/Ser142 confer sensitivity to 3.47. VSV particles pseudotyped 
with chimeric glycoproteins obtained by reciprocal exchange of Zaire and Sudan GP sequences were 
incubated with Vero cells in the presence of increasing concentrations of inhibitor 3.47. Vero cells 
were treated with inhibitors and exposed to VSV encoding luciferase and pseudotyped with the 
indicated chimeric GPs. Results are represented as % of vehicle (DMSO) control. 
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GP to >10 µM for EboV GPS141-142, exhibiting a dose response curve that more closely 
resembled the resistance of SudV GP to inhibition by 3.47 (Figure 3-9). These results 
show that alanine 141 and glutamine 142, found within the RBD of the SudV GP, are 
the major determinants that naturally render SudV GP resistant to compound 3.47, a 
phenotype which is dominantly conferred when encoded into the backdrop of the 
naturally drug- sensitive EboV GP. 
 
Discussion 
 Recently, studies by our lab and others have identified NPC1 as an essential 
host factor for Ebola virus entry (Carette et al., 2011). In Chapter 2, we found that EboV 
entry was strictly dependent on NPC1 expression and that EboV GP bound to NPC1 
only after it had been protease cleaved. In this chapter, we expand on these findings by 
utilizing 3.0, the compound that originally lead us the discovery of NPC1. Extensive 
SAR studies allowed us to select a set of informative derivatives of 3.0 with a broad set 
of potencies and chemical characteristics, that could be used in a set of biochemical, 
functional, and genetic assays designed to probe the NPC1-GP1 interaction. 
A. Inhibitors prevent GP-NPC1 interaction in a dose dependent manner 
Several compounds that have a tertiary amine are sequestered in the LE/LY of 
treated cells, depending on where the inhibitor target resides, this can have a 
deleterious or advantageous effect on the ability of the compound to reach its target. In 
the case of inhibiting a late step in the EboV entry, accumulation of inhibitors in the 
LE/LY could be a particularly desirable characteristic given that this is the compartment 
that contains the host-factors for virus entry (low pH, cathepsins, and NPC1) and that 
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microscopy experiments reveal co-localization of virions to Rab7 containing LE (Nanbo 
et al., 2010; Saeed et al., 2010).  One of the factors that can affect how efficiently a drug 
sequesters into these compartments is the pKa. One study that studied the 
compartmentalization of compounds that were essentially identical, except for their pKa 
values, showed that a pKa as low as 6.0 could lead to a greater than 20-fold increase in 
the concentration of compound in the lysosome (Duvvuri et al., 2005). Given that 3.0 
had a tertiary amine whose pKa was 6.0, it was formally possible that the compound 
could be accumulating in the LE/LY of cells, thus, changing the effective concentration 
of the compound in its target compartment. However, testing of the 3.0 (-) amine 
derivative proved that the tertiary amine was dispensable for antiviral activity, the ability 
of the compound to block binding, and the induction of cholesterol build-up. 
Furthermore, tests of 3.0 derivatives with different potencies revealed that their abilities 
to inhibit EboV GP1 binding with NPC1-containing membranes closely correlated with 
the antiviral activity of the compounds in cells, thus, suggesting that the ability to inhibit 
binding of GP to NPC1 membranes in vitro is a manifestation of the antiviral activity.   
Interestingly, the antiviral activity also correlated with the ability of the compound 
to inhibit cholesterol uptake. This result was surprising, as it seems to be at odds with 
the data from Chapter 2, which indicates that the cholesterol transport function of NPC1 
is not required for productive EboV entry. This apparent discrepancy could be due to an 
allosteric interaction of the compound with NPC1 that locks the protein into a 
conformation that is incompetent for both GP binding and cholesterol transport. 
Alternatively, our compounds could be competing directly with a binding site in NPC1 
that interacts with GP, but also overlaps directly with a cholesterol binding site or the 
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binding site of a second cellular factor involved in the cholesterol transport pathway. 
Recently published work suggesting that the luminal loop 2 (LL2) of NPC1 may be 
important for GP binding adds support to the later hypothesis, because this loop has 
also been implicated in the binding of NPC2, a soluble LE/LY protein that transfers 
cholesterol from the intraluminal membranes to NPC1 (Miller et al., 2012; Deffieu and 
Pfeffer, 2011). However, more structural and functional work needs to be done to 
identify the residues on NPC1 important for both GP and inhibitor binding. Identifying 
the exact sites on NPC1 that are involved in these interactions will provide insight into 
the mechanism by which the inhibitors are able to inhibit both cholesterol uptake and 
GP-NPC1 binding. 
B. EboV inhibitors bind directly to NPC1 
A derivative of 3.47 that could be used for functional crosslinking studies, 3.98, 
directly labeled NPC1, providing further evidence that the compounds inhibit entry by 
interacting with NPC1. However, it is crucial to note that 3.98 crosslinks several other 
cellular proteins, including many proteins found in CHOnull cells, thus indicating that the 
compound targets numerous proteins, most of which are not likely to be involved in 
EboV entry. Critically, we observed that overexpression of NPC1 reduced the sensitivity 
of the virus to inhibitors, consistent with the hypothesis that NPC1 is a direct target for 
3.0 derived compounds and that the NPC1-GP interaction disrupted by these 
compounds is functionally important for virus entry. The direct interaction between 
NPC1 and the inhibitors must be structurally mapped in order to determine exactly the 
manner in which the inhibitors disrupt binding of GP to its receptor. 
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Figure 3-10. Inhibitor sensitive mutations 141-142 are solvent exposed on top outer edge of 
GP1 in the post-cathepsin cleaved trimer.  The atomic resolution structures of the GP trimer for 
SudV-GP1 (green and yellow, PDB:3S88) and EboV-GP1 (purple and gray, PDB:3CSY) other 
domains of GP1 that are cleaved off during cathepsin digestion are excluded from this diagram. 
Residues 141-142 are represented here as sticks and spheres. SudV residues AQ141-142 that are 
associated with the resistance phenotype are shown in blue and EboV residues VS141-142 that are 
associated with sensitivity to the inhibitors are shown in red. 
141 
142 
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C. Genetic assay for viral determinates of inhibitor sensitivity  
In order to gain mechanistic insight into the way in which the virus engages 
NPC1, we again used the inhibitor 3.47 as a probe, this time in genetic assays that 
identified mutations in GP1 capable of conferring resistance to the inhibitors. 
Experiments that explored the relative sensitivity of GPs from naturally occurring 
filovirus species revealed that SudV GP was resistant to the antiviral activity of the 
compounds.  Consistent with the hypothesis that NPC1-GP binding is like that of a 
receptor-virus interaction, we found that resistance mutations mapped to the previously 
identified RBD (Kuhn et al., 2006; Dube et al; 2009). Since the atomic resolution 
structures of the pre-fusion forms of both EboV GP and SudV GP had previously been 
solved (Lee et al., 2008; Dias et al., 2011; Bale et al., 2012), we were able to directly 
compare the impacts that residues 141 and 142 may have on the overall structure of the 
GPs. Residues 141 and 142 are located near the top outer edge of the GP1 RBD and 
are surface exposed after protease cleavage (Figure 3-10). Speculations regarding the 
impact that the mutations may have on GP are discussed below. 
D. Structural analysis of resistance residues 141-142 in the GP1 RBD of EboV GP 
and SudV GP 
 Although the GPs of SudV and EboV have very similar structures overall, the 
region immediately after residues 141 and 142 exhibit a change in secondary structure. 
After these residues, Zaire GP continues to have a "-strand secondary structure that 
shares multiple hydrogen bonds with another strand in close proximity, which together 
form a continued parallel "-sheet. By contrast, after residues 141-142 in Sudan, both "-
strands that form the "-sheet in Zaire become a random coil that no longer form  
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AQ141-142 
Sudan Zaire 
VS141-142 
Zaire 
VS141-142 AQ141-142 
Sudan 
Figure 3-11. Sudan GP1 has fewer polar contacts between !7 and !8 after residues 141-142 
and exhibits more thermodynamic mobility in these regions. (a) A model of the polar contacts 
between EboV-GP1 !7 and !9 (purple, left, PDB:3CSY) and SudV-GP1 !7 and !8 (green, right, 
PDB:3S88). SudV residues AQ141-142 that are associated with resistance are in blue and EboV 
residues VS141-142 that are associated with sensitivity are in red. Residues 109-114 and 139-144 
are represented as sticks to illustrate polar contacts. (b) Comparison of thermal parameter 
distributions for the regions of SudV and EboV GP1s that are adjacent to residues 141-142. This is 
illustrated as a B-factor ‘‘putty’’ depicted on the structure from dark blue (lowest B-factor) to red 
(highest B-factor), with radius of the ribbon increasing from low to high B-factor. 
a 
b 
! &%!
hydrogen bonds with the adjacent strand (Figure 3-11a). The side-chain characteristics 
of the mutated residues appear to potentially have a direct consequence on the change 
in secondary structure, as replacement of Ser-142 in Zaire results in the loss of a side-
chain hydrogen bond with the backbone carbonyl group of Glu-112, a bond unable to be 
formed by the rotamers of Gln-142 found in Sudan (Figure 3-11a). This loss of 
secondary structure in Sudan could account for the increase in flexibility of this region in 
SudV GP when compared to the relatively rigid structure of EboV GP, as seen in the 
relative B-factor values (or temperature factor), a measure of the thermal vibration of 
atoms in the protein crystal, for this portion of GP1 (Figure 3-11b). Indeed, recently 
published studies involving peptide amide hydrogen-deuterium exchange mass 
spectrometry, which measures the flexibility and solvent exposure of a peptide by 
quantifying of the exchange of deuterium in solvent water with the hydrogen bound to 
peptide amides, have indicated that some regions of SudV-GP1 show increased 
exchange of ions as compared to EboV-GP1, consistent with the observed B-factor 
values (Bale et al., 2011 and 2012). It is possible that the flexibility that is observed 
when AQ141-142 is present allows for the virus to overcome any steric hindrance that is 
provided by interaction of 3.47 with NPC1. Interestingly, residues 141 and 142 are 
located between two residues (K140 and G143) that are conserved amongst filoviruses 
and have been suggested to have an impact on GP binding (Brindley et al., 2007; Lee 
et al., 2008; Dube et al., 2009). However, the impact that these residues have on GP-
NPC1 affinity must be interrogated for a full understanding of the resistance 
mechanism. 
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E. Revision of entry model based on inhibitor studies 
Analysis of the EboV GP structure shows that the residues in the N-terminal 
domain of GP1 that mediate binding to the receptor (NPC1) are interspersed with the 
residues that make stabilizing contacts with GP2 (Lee et al., 2011). This structural 
feature is consistent with the possibility that binding of cleaved GP1 to NPC1 relieves 
the GP1-imposed constraints on GP2 and promotes virus fusion to the limiting 
membrane. The findings that NPC1 is directly labeled with the cross-linkable derivative 
of 3.47, that 3.47 disrupts binding of GP to NPC1 containing membranes, and that 
overexpression of NPC1 confers resistance to 3.47, suggests that EboV inhibitors target 
NPC1 in a manner that prevents the essential interaction between GP and NPC1. 
Additionally, chimeric analysis of GPs that are resistant to 3.47 inhibition localized 
resistance to two residues on the top of RBD that are exposed only after cathepsin 
cleavage, thus indicating that 3.47 directly targets this virus-receptor interaction (Figure 
3-12). The role of cathepsin proteases in cleavage of GP1 to expose the NPC1 binding 
site during EboV infection is analogous to the role of CD4 in inducing a conformational 
change in gp120 to expose the co-receptor binding site during human 
immunodeficiency virus infection (Harrison, 2008). Additionally, the mode of action of 
compound 3.47 is analogous the CCR5 antagonist maraviroc, as 3.47 binding to NPC1 
blocks association of the GP with the host-receptor (Dorr et al., 2005). These studies 
provide an example of how small molecules identified by screening and medicinal 
chemistry optimization can be used as molecular probes to analyze virus–host 
interactions. 
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Figure 3-12. Revised model of EboV entry and action of 3.47. Following EboV uptake and 
trafficking to late endosomes, EboV GP is cleaved by cathepsin protease to remove heavily 
glycosylated domains (CHO) and expose the putative receptor binding domain (RBD) of GP1. 
Binding of cleaved GP1 to NPC1 is necessary for infection and is blocked by the EboV inhibitor 3.47. 
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Discussion and Future Directions 
 
A. State of the Ebola virus entry field 
 In the last seven years several important contributions have been made to the 
Ebola virus entry field that have begun to fill in long standing gaps in the knowledge of 
the EboV entry pathway. These contributions include the report of the atomic resolution 
structure of a pre-fusion EboV and SudV GP (Lee et al., 2008; Dias et al., 2011), live 
cell microscopy studies of EboV uptake and entry (Nanbo et al., 2010; Saeed et al., 
2010), and the identification of essential host factors that function in the late endosome 
and/or lysosome (LE/LY) of cells to facilitate filovirus entry (Chandran et al., 2005; 
Schornberg et al., 2006; Carette et al., 2011; Cote et al., 2011). These studies have 
revealed a complicated multistep process that has continued to reveal new paradigms 
for how enveloped viruses utilize host factors to mediate productive entry events.  
 
B. Ebola virus entry pathway 
 The Ebola virus glycoprotein, GP, is the only viral protein that is expressed on 
the surface of mature filovirus particles and is both necessary and sufficient for 
mediating viral entry into host cells (Takada et al., 1997; Wool-Lewis and Bates; 1998). 
GP mediates attachment to target cells, virus internalization, trafficking to an endosomal 
compartment, and fusion with the LE/LY of cells. Recent advances have provided clues 
as to how GP mediates the steps required for productive infection of target cells. The 
first step in entry is viral attachment, which is likely to occur through many redundant 
interactions, as no single factor has been identified that mediates this step in all 
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permissive cell types. Several different C-type lectins have been suggested to play a 
role in the initial attachment step and are believed to interact with the N- and O-linked 
glycans present on GP (Alvarez et al., 2002; Marzi et al., 2004; Lin et al., 2003; 
Matsuno et al.; 2010). These C-type lectins are expressed on macrophages and 
dendritic cells (DCs), key cell types for in vivo pathogensis (Geisbert et al., 2003), but 
not in other susceptible cell types; thus, suggesting a role for redundant attachment 
factors. Recently, the T-cell costimulatory molecule and phosphatidylserine receptor, 
TIM-1, was identified as a candidate cell surface receptor for EboV and MarV 
(Kondratowicz et al., 2011). This protein was shown to interact with EboV GP, enhance 
infection on weakly permissive cell lines, and may be important for infection of epithelial 
cells but not DCs or macrophages (Kondratowicz et al., 2011). The redundant nature of 
the interactions that mediate attachment leave a possibility for the identification of yet 
other proteins that mediate cell surface attachment, an important first step in virus entry. 
 After the initial step of virus attachment, EboV virions must be internalized and 
undergo trafficking through the endosomal pathway to the late endosomes and 
lysosomes (LE/LYs) of cells. Recent microscopy studies have reveled that particles are 
internalized through a macropinocytosis-like process that is strictly dependent on GP 
induced membrane ruffling (Nanbo et al., 2010; Saeed et al., 2010; Mulherkar et al., 
2011). Following internalization, the virus is trafficked through the endosomal pathway 
to the late endosomal compartment where they colocalize with Rab7/LAMP-1 positive 
late endosomes, a trafficking event that is important for productive entry, as expression 
of a dominant-negative form of Rab7 is able to reduce viral infection (Saeed et al., 
2010). Furthermore a number of other host factors and signaling networks involved in 
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maturation of the late endosome have been implicated in virus entry, including the 
phosphatidylinositol-3-kinase and the calcium-calmodulin signaling pathways, and the 
homotypic fusion and vacuole protein sorting (HOPS) complex (Saeed et al., 2008; 
Kolokoltsov et al., 2009; Carette et al., 2011).  
In the LE/LY compartment, the EboV GP undergoes a series of structural 
changes mediated by host factors that are essential for viral fusion. Previous studies 
identified endosomal cysteine proteases, specifically cathepsin B, as essential host 
factors for EboV entry; these proteases mediate a GP cleavage event that both primes 
the trimer for fusion and reveals a receptor binding domain (RBD) that is believed to 
bind to an unknown receptor within the LE/LY of cells (Chandran et al., 2005; 
Schornberg et al., 2006; Kuhn et al., 2006; Dube et al., 2009; Kaletsky et al., 2007; 
Hood et al., 2010; Dube et al., 2010). In this thesis, we describe work that has 
contributed to the EboV entry model through the identification of the membrane protein 
Niemann-Pick C1 (NPC1) as the previously unidentified LE/LY receptor, and the finding 
that binding of protease cleaved GP to NPC1 is an essential step for virus entry.  
 
C. The role of NPC1 as an essential host factor for Ebola virus entry 
 We identified NPC1 as an essential host factor for filovirus entry after following 
up on a cellular cholesterol accumulation phenotype that was induced by treatment of 
cells with small molecule inhibitors of EboV entry. The finding that NPC1 is essential for 
EboV entry has been corroborated by an independent genetic screen that was co-
published with our paper (Carette et al., 2011) and by a recently published paper that 
isolated CHO cells resistant to EboV infection and identified a defective NPC1 as the 
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mediator of this phenotype (Haines et al., 2012). NPC1 is a large polytopic membrane 
protein that resides in the limiting membrane of the LE/LY where it functions as a 
cholesterol transport protein that facilitates the movement of LDL-derived cholesterol 
out of the LE/LY compartment (Kolter and Sandhoff, 2010; Ko et al., 2001). Through the 
use of a combination of cell lines defective in other aspects of the cholesterol transport 
pathway, siRNA knock down of the important components of this pathway, and cell lines 
that express the cholesterol transport defunct NPC1 point mutant P692S, we were able 
to demonstrate that EboV GP mediated infection requires NPC1 expression but does 
not require the cholesterol transport activity of NPC1.  
By probing GP binding to NPC1 through a series of membrane binding and co-
immunoprecipitation experiments, we show that GP associates with NPC1 only after it 
has undergone protease cleavage. Both unpublished data from our own lab and a 
recent study published by Miller et al. has confirmed these findings in vitro with a 
soluble version of the second luminal loop of NPC1, which they suggest is the key 
mediator of NPC1 dependent binding and entry, thus indicting that the interaction 
between NPC1 and EboV GP is a direct interaction (Miller et al., 2012).  These findings 
support the hypothesis that cathepsin cleavage functions to remove a heavily 
glycosylated domain that masks the receptor binding site, as indicated by both atomic 
resolution structures of the mucin deleted GP, and cryo-electron microscopy of VLPs 
containing full length GP (Lee et al., 2008; Dias et al., 2011; Beniac et al., 2012). 
The location of NPC1 in the limiting membrane of the late endosome makes it 
tempting to speculate that the NPC1-GP interaction may lead to productive fusion of the 
viral envelope with the limiting membrane of the LE/LY, thus, leading to delivery of the 
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nucleocapsid to the site of viral replication. Indeed, this model is supported by the 
atomic resolution structure of the pre-fusion conformation of the EboV-GP trimer, as the 
residues that have been suggested to make up the RBD appear to be interspersed with 
residues that stabilize the pre-fusion conformation of GP2 (Lee et al., 2008). By analogy 
to other class I fusion proteins, such as MLV and HIV, it is possible that the role of 
NPC1 during infection is like that of a “classic” receptor like the HIV co-receptor (Futura 
et al., 1998; Mkrtchyan et al., 2005) or like M-CAT for MLV (Albritton et al., 1989; 
Lavillette et al., 1998), where binding of the RBD to the receptor (in the case of EboV- 
NPC1) would trigger membrane fusion. However, it is important to note that with the 
current findings, we cannot rule out the possibility that other steps remain to be 
identified in the EboV entry pathway. Indeed, it remains fully possible that a more 
complex model explains the function of NPC1, a model in which an interaction with 
NPC1 may prepare the virus to undergo a subsequent, yet identified fusion-triggering 
step. Until we develop an in vitro fusion assay we cannot rule out the possibility that 
binding to NPC1 potentiates the GP for further cysteine protease cleavage or an 
interaction with another cellular host factor as has been proposed as potential triggers 
for membrane fusion (Wong et al., 2009; Brecher et al., 2012).  
In order to begin to rigorously test the role of NPC1 function in EboV entry we 
must first set up a series of in vitro biochemical and structural assays. A highly detailed 
structural map of the EboV GP1 RBD bound to its NPC1 ligand is an essential step to 
understanding the ways in which the RBD binds to NPC1 and how the binding mutants 
K114A, K115A, and K140A may disrupt this interaction (Dube et al., 2009; Miller et al., 
2012). At first, this seems to be a daunting task, given the hydrophobicity, complexity, 
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and size of the full length NPC1 protein. However, the difficulties in handling the full-
length proteins can potentially be circumvented, as a soluble version of the second 
lumenal loop of NPC1 (soluble lumenal loop 2 or sLL2) appears sufficient to mediate 
binding to GP (J.M. unpublished data; Miller et al., 2012). Although an atomic resolution 
structure of the RBD bound to its NPC1 ligand would provide valuable insight into the 
manner in which the two proteins interact, we must also develop useful in vitro assays 
with which we can interrogate the role of each component of the entry pathway. To this 
end, our lab is pursuing the development of in vitro assays for EboV GP that are akin to 
the ones used to carefully dissect the ALV-A entry mechanism (Mothes et al, 2000; 
Smith and Cunningham, 2007; Delos et al., 2008).  We should be able to take 
advantage of a recently developed liposome binding assay for soluble EboV GP trimer 
that measures the amount of fusion peptide association with liposomes (Brecher et al., 
2012), and expand these studies to test for the effect of NPC1 on liposome association. 
We are also pursuing developing a liposome-virus fusion assay to measure if NPC1 
alone or in combination with low pH and proteases is capable of mediating virion-
liposome fusion. We will be able to use a recently described HR2 derived peptide (Miller 
et al., 2011) as a control in both of these experiments to assay for the formation of an 
extended intermediate and the fusion peptide mutant F535R to reveal the role that the 
fusion peptide insertion may have in these associations (Ito et al., 1999). Regardless of 
the exact molecular role that GP binding to NPC1 may play in virus entry, our findings 
have demonstrated that this interaction is an essential functional step in the entry 
process, and dissection of the molecular consequences of this interaction are key to 
understanding its role in entry. 
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D. Small molecule mediated inhibition of the GP-NPC1 interaction 
 This thesis describes the identification and characterization of chemical probes 
used to interrogate the interaction between GP and NPC1 in biochemical, functional, 
and genetic assays. In Chapter 3 informative derivatives of compound 3.0 were used as 
probes that help to establish that these compounds target NPC1 in a manner that 
prevents the binding of cleaved GP to NPC1 containing membranes. Compound 3.98, a 
photoactivatable derivative of 3.0 that contains a specific site for covalent labeling by 
click chemistry to enable target identification, crosslinked to NPC1 indicating a direct, 
though, not exclusive interaction with NPC1, as several other cellular proteins were 
labeled in CHOnull derived membranes. Furthermore, derivatives of 3.0 were able to 
inhibit binding of cleaved GP in the membrane binding assay in a dose dependent 
manner that closely correlated with the antiviral activities of the compounds, thus, 
suggesting that the interaction between cleaved EboV GP and NPC1 is important for 
virus entry. The functional importance of the interaction between NPC1 and protease 
cleaved GP was further corroborated by recent findings that mutations in the RBD 
known to attenuate Ebola virus infectivity result in a GP that binds with lower affinity to 
the NPC1 ligand and that overexpression of NPC1 can compensate for the low affinity 
interaction (Miller et al., 2012). Similarly, we found that overexpression of NPC1 
mediated resistance to our compounds, but did not increase overall infectivity in these 
cells. Taken together these findings indicate that in certain cases, either decreased 
affinity of a mutant RBD for NPC1 or through an inhibitor mediated decrease in the 
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numbers of NPC1 that can mediate binding to the RBD, the NPC1-GP interaction can 
become the limiting step in virus entry, thus highlighting the importance of this step.  
 We have established that the 3.0 derived inhibitors are capable of blocking a 
NPC1-GP interaction that is essential for virus entry. However, the mechanism by which 
these compounds inhibit GP binding to NPC1 remains elusive. At least two models exist 
for the possible mechanism of action of the small molecule entry inhibitors; these 
compounds can act through a competitive or a non-competitive inhibition model. In a 
competitive inhibition model, the compounds would have to bind to and compete directly 
with the GP binding site on NPC1. This mechanism of inhibition would be analogous to 
the way in which derivatives of the endogenous chemokine RANTES interferes with the 
binding of CCR5 tropic HIV-1 gp120 with its co-receptor (Lederman et al., 2004). By 
contrast, the non-competitive model for small molecule inhibition would involve inhibitor 
binding to an allosteric binding site on NPC1, which could stabilize a conformation of 
NPC1 that is unable to bind to GP. This type of inhibition would be analogous to 
inhibition of HIV-1 by maraviroc and other non-competitive inhibitors of CCR5 co-
receptor binding (Watson et al; 2005; Kondru et al., 2008; Garcia-Perez et al., 2011). 
Currently, we cannot distinguish between these two models of inhibition; however, 
recent findings that a sub-domain of NPC1 may be responsible for GP binding has 
made it possible to perform biochemical experiments that may be able to distinguish 
between these two models.  
As mentioned above, recent work from our lab and others have found that LL2 of 
NPC1 is necessary and sufficient for binding to cleaved GP and that a soluble tagged 
version of this loop is able to pull down cleaved GP through co-immunoprecipitation, 
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suggesting a direct interaction between GP and the sLL2 (J.M. unpublished data; Miller 
et al., 2012). We can use a tagged-sLL2 and the soluble GP to interrogate the manner 
in which sLL2 binds to GP by using surface plasmon resonance (SPR) to quantitatively 
determine the dissociation constant (KD) of GP with sLL2. Furthermore, if the inhibitors 
are able to disrupt co-immunoprecipitation of the cleaved GP trimer to sLL2 then this 
would indicate that we could use these compounds in similar SPR studies to 
quantitatively determine the effect of the inhibitors on the KD between GP and sLL2, a 
method that has been used to measure the small molecule mediated disruption of the 
protein-protein interaction between cyclophilin A and cyclosporin A (Wear et al., 2005). 
Additionally, we are currently trying to use the crosslinkable derivative 3.98 to 
interrogate exactly where the inhibitors bind to NPC1. In these studies we are 
crosslinking 3.98 to NPC1 as was done in Chapter 3 and, then, using mass 
spectroscopy to identify exactly which residues on NPC1 contain the covalent 
modification. Once we have identified the key residues, we can then mutate those sites 
in NPC1 and investigate the impact that these sites have on EboV entry, EboV GP 
binding, and small molecule inhibition. If the sites for inhibitor binding lie within the LL2 
and the subsequent mutagenesis reveals that these sites are key contributors to the 
binding affinity of GP for NPC1, then this would provide direct proof that the inhibitors 
are competitive inhibitors of binding. Conversely, if these experiments reveal that the 
target of 3.98 is outside of LL2 and the small molecule inhibitor is unable to disrupt 
binding of sLL2 to GP then it is likely that these inhibitors act in a non-competitive 
manner. Regardless of which model the inhibitors use to block GP association with 
NPC1, understanding the molecular basis with which resistant GPs bind to NPC1 in the 
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presence of compound should give us mechanistic insights into the manner in which 
GP1 engages with NPC1, and reveal possible ways in which the virus could overcome 
the inhibition of this potential therapeutic candidate. 
 Because EboV is a BSL4 pathogen, selecting for virus mutations that confer 
resistance to potential antiviral compounds in the context of full-length replication 
competent virus is both costly and potentially dangerous. Instead, we decided to look to 
the naturally occurring sequence variations within various filoviridae GPs to identify 
specific coding mutations that confer resistance to the compounds. We discovered that 
the SudV GP was resistant to compound 3.47 and, using a series of systematic 
chimeras, we were able to map the resistance to two residues (A141 and Q142) that are 
surface exposed after protease cleavage and located near the top outer edge of the 
GP1 RBD. Notably, these residues can also confer sensitivity to the compound, as 
replacing the residues with V141 and S142 from EboV could render SudV GP sensitive 
to 3.47. Whether or not these mutations lead to an overall change in the affinity of the 
mutant GP for a NPC1 ligand, thus making them either more or less capable of directly 
competing with the inhibitor for ligand binding, remains to be demonstrated. If resistant 
GPs demonstrate a greater binding affinity for NPC1 than their sensitive counterparts, 
this would indicate a resistance mechanism that has arisen from a direct mutant GP 
mediated competition with the inhibitor binding site, analogous to the HIV resistance 
mutations to PSC-RANTES (Dudley et al., 2009). By contrast, if the mutations in the 
RBD do not affect the overall affinity of the site for NPC1 but instead confer the 
capability to bind to an inhibitor bound conformation of NPC1, then these resistance 
mutations are likely to act in a non-competitive manner, a resistance mechanism that is 
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often seen in resistance mutations located in the V3 loop for HIV for the non-competitive 
family of CCR5 agonists such as Maraviroc and Vicriviroc (Tsibris et al., 2008). An in 
vitro binding affinity assay, like the SPR described above, must be developed to 
quantitatively measure the binding affinities of SudV GP, Ebo GP, and chimeric GPs in 
order to understand the molecular mechanism of resistance. 
 
E. NPC1 as a potential therapeutic target  
 The studies described in this thesis have not only contributed to the Ebola virus 
entry field through the identification of NPC1 as an essential host factor for entry but 
they have also contributed to the very early stages of antiviral drug development. 
Through the identification and validation of NPC1-GP binding as a ‘druggable’ target, 
we have identified a potential starting point for the development of therapeutics for the 
treatment of EboV infection. Ebola is a virus for which control of outbreaks and 
treatment of patients is limited to isolation, containment, and palliative care for the 
patient, as no therapeutics or vaccines are currently available to prevent the spread of 
the virus. Though we will have a long way to go from the identification of a small 
molecule inhibitor of entry to the development of therapeutics that can treat infection, 
the data presented in this thesis can, at least, serve as a starting point for further 
optimization of potential inhibitors of entry. Our initial tests of the sensitivity of different 
filovirus species to the EboV inhibitors show that there is natural variability in how the 
virus may respond to the inhibitors. If we can gain structural insight into how the EboV 
and SudV RBD interact with NPC1 in the presence of inhibitors, then we can use these 
findings to rationally design a compound that has a broader range of activity against the 
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different filovirus GPs. We are currently trying to expand the 3.47 studies to include 
animal trials for pharmacokinetics and inhibition of EboV pathogenesis. If these entry 
inhibitors were ever to be used as actual therapeutics it would be important to combine 
them with inhibitors of other EboV proteins, such a the polymerase L proteins, to 
minimize resistance mutations, analogous to combination therapies for HIV and HCV. 
However, it is important to note that since Ebola virus produces an acute infection (2-21 
days) rather than a chronic infection, the amount of time that a patient maybe exposed 
to therapy and that a virus has to mutate maybe significantly less than that of chronic 
infections like HIV or HCV. Although conclusions from evolutionary studies of EboV and 
MarbV must be approached with a great deal of caution due to the relatively low sample 
size of sequences, one study has estimated that rate of nonsynonymous mutations in 
the virus GP is about 100-fold lower than that of HIV or influenza (Suzuki and Gojobori, 
1997), suggesting that the virus may be slightly less prone to acquiring resistant 
mutations.   
  
Conclusions  
 Our work showing that NPC1 is essential for EboV entry has implications for the 
EboV entry field as well as virus entry in general. In our studies, we describe a 
mechanism for entry that involves a multi-step process that ultimately leads to 
productive infection. As we have continued to uncover each of the layers to the puzzle 
of how filoviruses get into their host cells, we are revealing new insights into how 
viruses use host factors to mediate virus entry. In 2005, our lab was the first to identify 
cathepsins as important entry host factors (Chandran et al., 2005). Follow up work and 
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an atomic resolution pre-fusion structure of EboV GP revealed that this cleavage event, 
which removes a heavily glycoslated immunoprotective domain, has the functional 
consequence of revealing the RBD. Subsequent studies of the role of cathepsins in 
entry of other enveloped viruses indicates that these endosomal proteases may have 
role in the entry of viruses such as Sars-CoV and Nipah/ Hendra virus, suggesting that 
endosomal proteases may have a more expansive role in enveloped virus entry than 
initially appreciated (Simmons et al., 2005; Huang et al., 2006; Pager and Dutch, 2005; 
Pager et al., 2006).  
Our recent studies pick up where the story for the role of cathepsin inhibitors in 
EboV entry left off. In this work we go from a small molecule lead, identified by high-
throughput screening, to discovering that the target of the compound is NPC1, and 
confirming that NPC1 binds to the post-cathepsin cleaved GP. Thus, we have 
simultaneously identified a novel host factor involved in virus entry while confirming that 
the factor is a potential therapeutic target. To our knowledge, this is the first example of 
an enveloped virus receptor that binds to its viral ligand in an intracellular compartment 
rather than at the cellular membrane. Given that several viruses require the low pH 
environment of the endosome, it will be interesting to see if other viruses have adopted 
this unique mechanism of protecting highly conserved RBDs. Although, there remain 
several unanswered questions in filovirus entry, these studies have gotten us one step 
closer to understanding the host triggers that mediate fusion, and one step closer to 
developing antiviral therapeutics to this deadly pathogen.  
!
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Materials and Methods 
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Methods Summary: Screening of small molecules was performed at the New England 
Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases at 
Harvard Medical School. Infection was assayed using VSV pseudotyped viruses 
encoding GFP or luciferase. Experiments with native ebolavirus were performed under 
BSL-4 conditions at the United States Army Medical Research Institute for Infectious 
Diseases. Cells were infected with EboV Zaire-Mayinga GFP and growth was measured 
by mean fluorescence.  EboV GP!TM and SudV GP!TM are derivatives of EboV GP or 
SudV GP in which the transmembrane domain has been replaced by a GCN4-derived 
trimerization domain followed by a His6 tag for purification.  Late endosomes/lysosomes 
(LE/LY) were isolated by differential centrifugation and further purified by Percoll density 
gradient centrifugation. LE/LY were disrupted by incubation with methionine methyl 
ester and coated onto high binding ELISA plates. Following attachment, unbound LE/LY 
membranes were removed and plates were blocked.  Bound membranes were 
incubated with the indicated amounts of native or thermolysin-cleaved EboV GP!TM or 
SudV GP!TM protein. Unbound GP!TM protein was removed, membranes were washed 
and bound GP!TM protein was recovered in SDS loading buffer and analyzed by 
immunoblot using GP1 antiserum.  Where applicable, membranes were pre-incubated 
with 3.0, 3.47, 3.18 or vehicle prior to the addition of GP!TM. To analyze EboV GP!TM 
binding to NPC1, LE/LY membranes were dissolved in 10mM CHAPSO, NPC1 was 
recovered by immunoprecipitation, and the immune complexes were analyzed by 
immunoblot probed with EboV GP1 antiserum. 
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Cell lines. Vero, 293T, HeLa (ATCC) and human fibroblasts (Gelsthorpe et al., 2008) 
(Coriell) were maintained in DMEM (Invitrogen) supplemented with 5% FetalPlex, 5% 
FBS (Gemini) or 10% FBS (HeLa, human fibroblasts). All CHO derived cell lines were 
grown as previously described (Millard et al., 2000; Millard et al., 2005). We have 
designated the CHO-K1 cell line as CHOwt, CHO-M12 as CHOnull, CHO-wt8 as 
CHONPC1, and the CHO-derived cell lines expressing NPC1 mutants as CHO NPC1 
P692S, CHO NPC1 L657F, and CHO NPC1 D787N.  CHO/NPC1-1, designated here as 
CHO hNPC1, expresses high levels of human NPC1 (Millard et al., 2000). Human 
fibroblasts from patients with lysosomal storage disorders were obtained from Coriell 
and are designated in this study as follows: healthy donor fibroblasts (GM05659) as wt, 
Niemann-Pick disease type C2 patient fibroblasts (GM18429) as NPC2-, Niemann-Pick 
disease type C1 patient fibroblasts (GM17914) as NPC1-(A), Niemann-Pick disease 
type C1 patient fibroblasts (GM03123) as NPC1-(B), and Niemann-Pick disease type A 
patient fibroblasts (GM16195) as ASM-. Genotypes of each of patient derived 
fibroblasts are described in Figures 2-7 and 2-8. 
 
Antibodies. Rabbit polyclonal anti-serum was raised against a peptide corresponding 
to residues 83 to 98 of ebolavirus Zaire Mayinga GP1 (TKRWGFRSGVPPKVVC). 
Antibodies to the following ligands were obtained commercially from the indicated 
manufacturer: anti-NPC1 (Abcam), anti-ORP5 (Abcam), anti-V-ATPase B1/2 (Santa 
Cruz), anti-AC (BD Biosciences), anti-Alix (Biolegend), and anti-Alexa Fluor 488 
(Invitrogen). Anti-ASM 1H7 was a gift from Genzyme. The monoclonal antibody against 
BMP was a kind gift from Toshihide Kobayashi. 
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Expression plasmids. Mucin domain-deleted EboV Zaire Mayinga GP (EboV GP) and 
VSV G were previously described (Chandran et al., 2005).  Plasmids encoding Côte 
d’Ivoire-Ivory Coast GP, Sudan-Boniface GP, Reston-Penn. GP and Marburg-Musoke GP 
were obtained from Anthony Sanchez and the mucin domain-deleted (!Muc) derivatives 
were created: Zaire!Muc GP (!a.a. 309-489), Côte d’Ivoire!Muc GP (!a.a. 310-489), 
Sudan!Muc GP (!a.a. 309-490), and Reston!Muc GP (!a.a. 310-490). Bundibungyo-
Uganda viral RNA was Trizol extracted and PCR used to generate a construct that 
expresses a mucin-deleted GP (!a.a. 309-489). This PCR added a silent Xba I site at the 
deletion site in each GP. A plasmid encoding Lassa fever virus GP1 was kindly provided 
by Gary Nabel. A codon-optimized sequence encoding GP2 was generated and 
combined with the GP1 sequence in pCAGGS to complete a GP expression vector.  
 
Production and purification of pseudotyped virions. VSV-!G pseudotyped viruses 
were created as described previously (Chandran et al., 2005).  LacZ-encoding retroviral 
pseudotypes bearing the designated envelope glycoproteins were prepared as 
previously described (Soneoka et al., 1995). 
 
Thermolysin digestion of virus and GP!TM. Purified EboV GP!TM (50µg/mL) or VSV 
particles pseudotyped with EboV GP were incubated at 37oC for 1 hour with the 
metalloprotease thermolysin (Sigma, 0.2mg/ml) in NT buffer (10 mM Tris.Cl [pH 7.5], 
135 mM NaCl). The reaction was stopped using 500 mM Phosphoramidon (Sigma) at 
4°C. Cleaved EboV GP!TM was stored in phosphate buffered saline supplemented with 
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1 mM EDTA, 1 mM PMSF (Sigma) and 1X EDTA-Free Complete Protease Inhibitor 
Cocktail (Roche). Digestions of purified SudV GP!TM (50mg/mL) or VSV particles 
pseudotyped with SudV GP were carried out exactly as described for EboV GP except 
that the time of incubation with thermolysin was only 30 minutes because SudV GP 
seems to be more sensitive to protease cleavage. 
 
Infection assays with pseudotyped virus. VSV pseudotyped viruses expressing GFP 
were added to cells in serial 10-fold dilutions and assayed using fluorescence 
microscopy. An infectious unit (i.u.) is defined as one GFP-expressing cell within a 
range where the change in GFP-positive cells is directly proportional to the virus 
dilution. For VSV expressing the luciferase reporter, pseudotyped virus was added to 
cells and luciferase activity was assayed 6-20 hours post-infection using the firefly 
luciferase kit (Promega). Signal was measured in relative luminescence units (RLU) 
using an EnVison plate reader (Perkin Elmer). In experiments involving inhibitors, stock 
solutions of 3.0 (20mM), 3.47 (10mM), 3.18 (10mM), 3.98 (10mM) and 3.0 (-) amine 
(10mM) in DMSO were diluted to a final concentration of 1% DMSO in media. All other 
inhibitors tested were dissolved into DMSO to make stock solutions of 20mM. Inhibitory 
activity was stable in the media of cultured cells for >72hours as assessed using single 
cycle entry assays. Infection of target cells with LacZ-encoding retroviral pseudotypes 
was performed in the presence of 5 mg/ml polybrene (Sigma). Seventy-two hours post-
infection, cells were stained for LacZ activity and titer was determined by counting 
positive foci and expressed as focus forming units (FFU) per ml of virus.!
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Ebolavirus infections under BSL-4 conditions. Vero cells or CHO cells were seeded 
to 96-well plates and exposed to EboV-GFP (Towner et al., 2005). For experiments 
investigating the growth of virus on CHOwt, CHONull, and CHONPC1 cells, virus was 
added to CHO cells at a moi of 1 (as measured on Vero cells). For experiments 
accessing the antiviral activity of our compounds against replication competent EboV, 
Vero cells were incubated with 3.0 (40 mM), 3.47 (40 mM), E-64-d (150 mM) or 1% 
DMSO 90 minutes prior to the addition of virus (moi=0.1). Virus-encoded GFP 
fluorescence was determined using a SpectraMax M5 plate reader  (Molecular Devices) 
at Ex 485nm, Em 515nm, cutoff 495nm at 22.5, 42, 71 and 97 hours post-infection.  
 
Screen for Ebola virus entry inhibitors. Screening of small molecules was performed 
at the New England Regional Centers of Excellence for Biodefense and Emerging 
Infectious Diseases at Harvard Medical School.  Vero cells were seeded in 384-well 
plates at a density of 5x104 cells per well using a Matrix WellMate (Thermo Scientific). 
The BIOMOL ICCB Known Bioactives1, NINDS Custom Collection, ChemBridge3, 
ChemDiv4, ChemDiv5 and Enamine2 compound libraries were transferred by robotics 
to the assay plates using stainless steel pin arrays. The compounds were screened at a 
constant dilution to achieve a final concentration between 10mM and 60mM.  After 
incubation for 2 hours at 37 °C, viruses were dispensed into each well (moi =1) and 
incubated for an additional 6 hours to allow virus gene expression. Cells were lysed by 
addition of Steady-Glo (Promega) and after 10 minutes at room temperature 
luminescence was measured using an EnVision plate reader. Each compound was 
tested in duplicate. Candidate compounds that inhibited EboV GP infection by more 
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than 80% were analyzed for potency, selectivity and absence of cytotoxicity (using 
Cyto-Tox assay, Promega) and 3.0 (2-((3r,5r,7r)-adamantan-1-yl)-N-(2-(4-
benzylpiperazin-1-yl)-2-oxoethyl)acetamide) was identified. Other compounds also 
identified from the small molecule screen include 4.0, 5.0, 6.0, 7.0, 8.0 and their 
structures are given in Table 2-1. The bioactive screen identified tamoxifen (Sigma), 
alverine (Sigma), sertraline (Sigma), and U18666A (Cayman Chemical) as antiviral 
compounds. The antiviral activity of the inhibitors was verified on human cells (HeLa, 
A549, 293T), mouse embryonic fibroblasts, and Chinese hamster ovary cells.  
 
Virus pre-incubation experiments with EboV inhibitors. Vero cells were seeded 
onto 12-well cell culture plates.  Compounds 3.47 (1µM), 4.0 (10µM), 5.10 (2µM), 6.0 
(1µM), 7.0 (2µM), 8.0 (10µM) and a vehicle control (DMSO) were added to cells or virus 
(VSV-GFP EboV GP or EboV GPTHL) in the following three manners. Cells were pre-
treated with media containing the inhibitors at 37°C for two hours prior to infection and 
virus was added to the cells in the presence of the inhibitor. Virus and inhibitors were 
added to cells simultaneously and inhibitors remained on the cells during infection. Virus 
was pre-incubated with the inhibitors in a small volume at 37°C for two hours before the 
addition of the mixture to the cells. The mixture was diluted 100x when added to the 
cells. GFP-positive cells were counted 18 hours post-infection and infectivity was 
calculated relative to cells exposed to DMSO vehicle alone. 
 
Inhibitor time of removal assays. Vero cells were incubated for one hour at 37°C 
with compounds 3.0, 4.0 , 5.0, 6.0, 7.0, 8.0 (20 µM), the lysosomatropic agent 
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ammonium chloride (NH4Cl, 30mM), or vehicle control (DMSO). Cells were then cooled 
to 25°C and VSV-GFP EboV-GP virus was added to allow the particles to bind in the 
presence of compounds. Cells were incubated with virus and inhibitors for 30 minutes at 
25°C. Wells were washed 2x with PBS to remove unbound virus and media containing 
the inhibitor was added back to the wells. Infection was initiated by raising the 
temperature to 37°C. At the indicated times post infection, media containing the 
compounds was replaced with media containing no inhibitors. GFP-positive cells were 
counted 18 hours post-infection. Infectivity is reported as percent GFP-positive cells 
relative to cells exposed to DMSO vehicle alone. 
 
Inhibitor time of addition assays.  Vero cells were exposed to VSV-GFP EboV 
GP for 30 minutes at room temperature. Wells were then washed 2x with PBS to 
remove unbound virus, and infection was initiated by raising the temperature to 37°C. 
Media was replaced with inhibitor containing media at the indicated times post-infection. 
Concentrations of compounds and measurement of infectivity are the same as in the 
washout experiments described above.  
 
LysoTracker Red accumulation assay.  Vero cells were grown on Lab-Tek 
(Thermo) chamber-slides. Cells were incubated for one hour with media containing the 
following compounds at their antiviral IC99, 3.0 (20µM), 4.0 (10µM), 5.0 (10µM), 6.0 
(5µM), 7.0 (5µM), 8.0 (20µM), chloroquine (20µM), NH4Cl (10mM) or vehicle control 
(DMSO) at 37°C. The known lysosomatropic agents chloroquine and NH4Cl were used 
as positive controls for endosomal pH disruption. The cells were exposed to 100 nM of 
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LysoTracker Red (Invitrogen) and Hoechst stain (500ng/mL) in the continued presence 
of the compounds for ten minutes at 37°C. Images of stained cells were obtained using 
epifluorescence microscopy (Nikon Eclipse TE2000U). The images were processed 
using ImageJ software. 
 
Synthesis of 3.0 derivatives. Compound 3.47 (methyl 4-((2-((4-(2-(2-((3r,5r,7r)-
adamantan-1-yl)acetamido)acetyl)piperazin-1-yl)methyl)phenoxy)methyl)benzoate) was 
prepared via a multi-step synthesis starting from N-Cbz-piperazine.  Thus, coupling of 
N-Cbz-piperazine with N-Boc-glycine followed by removal of the Boc group under acidic 
conditions yielded 4-Cbz-piperazine glycinamide.   After acylation of the terminal amine 
with adamantan-1-acetyl chloride, the Cbz group was removed by hydrogenolysis to 
give (1-(adamantan-1-yl)acetamido)acetyl)piperazine.   The piperazine was then 
benzylated via reductive amination with 2-(4-methoxycarbonyl)benzyloxybenzaldehyde 
using sodium triacetoxyborohydride to provide 3.47.   Compound 3.18  and 3.0 (-) 
amine was synthesized in a similar fashion.  Compound 3.98 was prepared via a multi-
step synthesis as follows. First, 2-hydroxy-5-nitrobenzaldehyde was alkylated by 4-
ethynylbenzyl bromide in the presence of potassium carbonate in DMF.  Resulting 
benzyloxy aldehyde underwent reductive amination with 2-((3r,5r,7r)-adamantan-1-yl)-
N-(2-oxo-2-(piperazin-1-yl)ethyl)acetamide using sodium triacetoxyborohydride.  The 
nitro group was then reduced to aniline (SnCl2), diazotized (NaNO2), and the diazonium 
finally converted to azide to yield 3.98.   
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Protease inhibitors and protease activity assays. The measurement of cathepsin B 
activity and the use of the inhibitor CA074 (Sigma) have been previously described 
(Chandran et al., 2005). 
 
Detection of intracellular cholesterol.  Cells were stained with filipin (50 µg/ml, 
Cayman Chemical) as previously described (Millard et al., 2005). Images of stained 
cells were obtained using epifluorescence microscopy (Nikon Eclipse TE2000U). The 
images were processed using ImageJ software. 
Production and purification of EboV and SudV GP!TM soluble protein.  EboV 
GP!TM is a derivative of the mucin-deleted EboV Zaire-Mayinga GP in which the 
transmembrane domain and C-terminus (a.a. 657-676) has been replaced by a GCN4-
derived trimerization domain (MKQIEDKIEEILSKIYHIENEIARIKKLIGEV) and a His6 
tag. An expression vector encoding a mucin-deleted SudV GP!TM that is fused to GCN4 
trimerization/His tag was also prepared (residues 1-309,491-657). The expression 
plasmid encoding EboV or SudV GP!TM was transfected into 293T cells using 
lipofectamine2000. Eighteen to twenty-four hours later the culture medium was replaced 
with 293SFMII (Invitrogen) supplemented with 1X non-essential amino acids and 2 mM 
CaCl2 and harvested daily for four days. Media containing soluble GP!TM was filtered 
and PMSF (1 mM)/ 1X EDTA-Free Complete Protease Inhibitor Cocktail was added. 
GP!TM was purified by affinity chromatography using Ni-NTA agarose beads (Qiagen), 
dialyzed against PBS using a 3kDa dialysis cartridge (Pierce) and stored at -80oC. 
Purity and integrity of EboV and SudV GP!TM were analyzed by SDS-PAGE. 
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Membrane Binding Assay. Indicated cells were washed with PBS x2, scraped in 
homogenization (HM) buffer (0.25 M sucrose, 1 mM EDTA, 10 mM Hepes pH7.0), and 
disrupted with a Dounce homogenizer. Nuclei and debris were pelleted by centrifugation 
at 1000 x g for 10 min. The post-nuclear supernatant was centrifuged at 15000 x g for 
30 min at 4°C and the pellet, containing the LE/LY, was resuspended in a total volume 
of 0.9ml composed of 20% Percoll (Sigma) and 0.4% BSA (Sigma) in HM and 
centrifuged at 36000 x g for 30 min at 4°C. Fractions (0.150 ml) were collected from the 
bottom to the top of the tube and those containing the highest "-N-acetylglucosamidase 
activity, as assessed by release of 4-methylumbelliferone from 4-methylumbellifferyl-N-
acetyl-b-D-glucosaminide (Sigma), were pooled and incubated in 20mM methionine 
methyl-ester (Sigma) for 1 hour at room temperature. Following LE/LY disruption, 1 X 
EDTA-Free Complete Protease Inhibitor Cocktail and 1 mM PMSF was added. The 
amount of purified LE/LY membranes used for the binding assay was normalized using 
the activity of the marker "-N-acetylglucosamidase and validated by immunoblot using 
V-ATPase B1/2 antibody. 
Disrupted LE/LY membranes were coated on high-binding ELISA plates 
(Corning) overnight at 4°C. Unbound membranes were removed and wells containing 
bound membranes were blocked for 2 hours at room temperature with binding buffer 
(PBS, 5% FBS, 1 mM PMSF, 1mM EDTA, 1X Complete Protease Inhibitor Cocktail). 
The indicated amount of purified EboV GP#TM, pretreated or not with thermolysin, was 
added to each well in binding buffer and incubated for 1 hour at room temperature. 
Unbound proteins were removed and wells were washed 3 times with PBS.  Membrane 
bound EboV GP#TM was solubilized in SDS-loading buffer. Bound and unbound EboV 
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GP#TM were detected by immunoblot using the EboV GP1 anti-serum, which recognizes 
an epitope an in GP1 that is conserved for all Ebola virus species. For binding assays in 
the presence of inhibitors, the immobilized membranes were pre-incubated at room 
temperature with the inhibitor or vehicle (10% DMSO) in binding buffer. After 30 
minutes, thermolysin cleaved EboV or SudV GP#TM was added in the continued 
presence of compound and bound and unbound or input GP was measured as 
described above.  
 
Co-Immunoprecipitation. CHOnull and CHOhNPC1 cells were homogenized as described 
above. The 15000 x g membrane pellet was resuspended in HM buffer and protein 
content was measured using the BCA assay (Pierce). The LE/LY membranes contained 
in the 15000 x g resuspended pellet were disrupted by incubation with 20 mM 
methionine methyl-ester for 1 hour at RT. Membranes of equal protein content were 
incubated with indicated amounts of EboV GP#TM, pre-treated or not with thermolysin, 
for 1 hour at RT in the presence of Complete Protease Inhibitor Cocktail (Roche) and 
incubated for an additional hour on ice before the addition of membrane lysis buffer 
(12.5mM CHAPSO, 150mM NaCl, 1mM EDTA, 10mM Tris/HCl pH7.4)  for a final 
concentration of 10mM CHAPSO. Proteins were solubilized on ice for 20 min and debris 
was removed by centrifugation at 12000 x g for 10 min at 4°C. The soluble membrane 
lysates were incubated with anti-NPC1 antibody for 1 hour at 4°C and then incubated 
with Protein A-agarose beads (Sigma) for an additional 4 hours at 4°C. Beads were 
then washed 3 times with 8mM CHAPSO, 150 mM NaCl, 1mM EDTA, 10 mM Tris/HCl 
pH7.4 and immunoprecipitated product was eluted by incubation in 0.1M glycine pH 3.5 
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for 5 min at RT. The eluted complex was then neutralized and analyzed by immunoblot 
using the indicated antibody.     
 
Photoactivation and click chemistry.  Photoactivation and click chemistry were 
performed as described previously with some modifications (Ban et al., 2010). CHOnull 
and CHO hNPC1 were homogenized in HM buffer as described above. Membranes in 
the 15,000g pellet were used without further purification and protein concentration was 
determined using the BCA protein quantification assay (Pierce). Membranes (250µg of 
protein content) were incubated with 25µM of 3.98 for 10min at room temperature, UV-
exposed for 1min on ice, and centrifuged at 15,000g for 30min at 4°C. Membranes were 
then lysed in lysis buffer (1% Triton X-100, 0.1% NP-40, 150mM NaCl, 0.4mM EDTA, 
50mM Tris pH 8.0) containing protease inhibitors (Roche). Lysates were pre-cleared by 
centrifugation at 10,000g for 10min at 4°C and the soluble proteins were used in the 
click chemistry reaction.  
For labeling of the whole membrane lysates, 50ug of protein was used for the 
click reaction of 3.98 with 20µM of Alexa Fluor 488 azide (Invitrogen) using the Click-iT 
Protein Buffer Reaction Kit (Invitrogen). Proteins were precipitated in 
methanol/chloroform/water (60:15:40), washed in methanol, dried, and resuspended in 
sample buffer prior to analysis by immunoblot. Labeled proteins were assayed using an 
anti-Alexa Fluor 488 antibody (Invitrogen) and an anti-NPC1 antibody was used for 
detection of NPC1 in membrane lysates. 
For analysis of NPC1 labeling, 200ug of proteins were incubated with 80µM of 
Alexa Fluor 488 azide, 7.5µM ascorbic acid, and 1.5µM copper sulfate for 30 min at 
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room temperature. NPC1 was purified by immunoprecipitation using anti-NPC1 (Abcam) 
and protein A-agarose beads (Sigma). The immunoprecipitate was eluted from the 
beads using 0.1M glycine pH3.5 for 5min at room temperature. Samples were 
neutralized before the addition of the sample buffer for immunoblot analysis using an 
anti-Alexa Fluor 488 antibody (Invitrogen) to detect labeled purified NPC1 and an anti-
NPC1 antibody to access success of the pull-down. 
 
Creating chimeric SudV and EboV GPs.  EboV GP1-SudV GP2 and SudV GP1- 
EboV GP2 chimeras were generated by restriction digestion of the pCAGGS plasmids 
encoding the mucin-deleted versions of the parental proteins with Xba I (New England 
Biolabs) to liberate GP1 and GP2 containing fragments for each virus GP. The 
fragments were gel purified and ligated using T4 DNA ligase (New England Biolabs).  
Chimeras of the GP1 functional domains were created using overlapping PCR to create 
fusion proteins of SudV and EboV GP1 at the appropriate junctions. Z90S encodes for a 
SudV GP whose first 90 AA have replaced with AA 1-90 from EboV GP. The inverse is 
true for S90Z. For the internal GP1 chimeric domain proteins the indicated fragment from 
the donor GP is placed within the context of the receiving GP. For example, Z(S90-213), 
Z(S90-189), and Z(S90-149) each encode for an EboV GP where amino acids 90-213, 90-
189, and 90-149, respectively, are replaced with the corresponding residues from the 
SudV GP. Chimeric swaps of one or two amino acid residues between the SudV RBD 
and EboV RBD were also created using overlapping PCR to introduce the new amino 
acids at the appropriate site. All GPs were then were cloned into expression vectors 
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using standard molecular biology techniques. All vectors were verified by DNA 
sequencing.  
 
Assay for BMP involvement in EboV entry. Vero cells were plated in a 96-well plate 
and grown overnight with 5 or 50 µg/ml of an antibody directed against BMP or a mouse 
monoclonal IgG isotype control (Santa Cruz). After 24 hours, the cells were infected 
VSV particles encoding GFP pseudotyped with EboV GP, VSV G, or Junin GP in the 
continued presence of antibody. After 24 hours cells were either counted for GFP-
positive cells or were washed, fixed (4% paraformadehyde in PBS), and stained with a 
Cy3-anti-mouse secondary antibody to assay for uptake of the BMP specific antibody 
into treated cells. Virus infection is reported as percent of GFP-positive cells relative to 
cells exposed to the isotype control antibody.  
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